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ABSTRACT OF DISSERTATION 
 
THE DEVELOPMENT OF NOVEL PROTEASOME INHIBITORS FOR THE TREATMENT 
OF MULTIPLE MYELOMA AND ALZHEIMER’S DISEASE 
 
Over a decade, proteasome inhibitors (PIs), bortezomib, carfilzomib (Cfz) and 
ixazomib, have contributed to a significant improvement in the overall survival for 
multiple myeloma (MM) patients. However, the response rate of PI was fairly low, 
leaving a huge gap in MM patient care. Given this, mechanistic understanding of PI 
resistance is crucial towards developing new therapeutic strategies for 
refractory/relapsed MM patients.   
In this dissertation work, we found H727 human bronchial carcinoid cells are 
inherently resistant to Cfz, yet susceptible to other PIs and inhibitors targeting 
upstream components of the ubiquitin-proteasome system (UPS). It indicated H727 
cells may serve as a cell line model for de novo Cfz resistance and remains UPS 
dependent for survival. To examine the potential link between proteasome catalytic 
subunit composition and cellular response to Cfz, we altered the composition of 
proteasome catalytic subunits via interferon-γ treatment or siRNA knockdown in 
H727 cells. Our results showed alteration in composition of proteasome catalytic 
subunits results in sensitization of H727 cells to Cfz. It supported that proteasome 
inhibition by alternative PIs may still be a valid therapeutic strategy for patients with 
relapsed MM after having received treatment with Cfz. With this in mind, we designed 
and synthesized a small library of epoxyketone-based PIs by structural modifications 
at the P1′ site. We observed that a Cfz analog, harboring a hydroxyl substituent at its 
P1′ position was cytotoxic against cancer cell lines with de novo or acquired resistance 
to Cfz. These results suggested that peptide epoxyketones incorporating P1′-targeting 
moieties may have the potential to overcome Cfz resistance mechanisms in cells. 
     
 
 
The immunoproteasome (IP), an inducible proteasome variant which is 
harboring distinct catalytic subunits, LMP2, MECL1 and LMP7 of the proteasome 
typically expressed in cells of hematopoietic origin, plays a role in immune response 
and is closely linked to inflammatory diseases. It has been reported that the IP is 
upregulated in reactive glial cells surrounding amyloid β (Aβ) deposits in brains of 
Alzheimer’s disease (AD) patients and AD animal models.  
To investigate whether the IP is involved in the pathogenesis of AD, we 
examined the impact of IP inhibition on cognitive function in AD mouse models.  We 
observed that YU102, an epoxyketone peptide targeting the IP catalytic subunit LMP2, 
improved cognitive dysfunction in AD mice without clearance of Aβ deposition or tau 
aggregation. Our cell line model study also showed a potential mode of action of 
YU102 which is suppressing pro-inflammatory cytokine production in microglial cells. 
It suggested that LMP2 contributes to microglia-mediated inflammatory response. 
These findings supported that LMP2 may offers a valuable therapeutic target for 
treatment of Alzheimer’s disease, expanding the therapeutic potential of the LMP2-
targeting strategy.  
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CHAPTER 1. INTRODUCTION 
1.1 The Ubiquitin-Proteasome System (UPS) 
The highly regulated degradation of cellular proteins is significantly crucial for 
cells to proliferate and differentiate. Before the discovery of the ubiquitin-
proteasome system (UPS), cellular protein degradation was thought to highly rely on 
lysosomes which were discovered by Christian de Duve in 1949 [1].  In 1977, Alfred 
Goldberg suggested the presence of another intracellular degradation mechanism in 
cells and Goldknopf and Busch identified an ubiquitin, a small protein with 76 amino 
acids, but the function was not defined [2]. In the same period, the 1970’s and 1980’s, 
Aaron Chiechanover, Avram Hershko, and Irwin Rose also worked on how cells 
degrade or destroy the proteins that are not useful anymore, which finally resulted in 
discovery and characterization of the ATP-dependent, ubiquitin-mediated protein 
degradation system [3-5]. The fundamental importance of the UPS in protein 
degradation mechanisms was highlighted when Rose, Hershko, and Ciechanover 
were awarded the 2004 Nobel Prize in Chemistry for their contributions in that field, 
the discovery of both ubiquitin and the proteasome [6]. 
The UPS, they found, is responsible for the degradation of ~80% of 
intracellular proteins [7]. Protein degradation by the UPS is mediated by the covalent 
conjugation of ubiquitin [8]. Protein substrates, destined to be degraded by the UPS, 
are labeled with multiple copies of ubiquitin, which are recognized by the proteasome 
and initiates their degradation [9] (Figure 1.1). Polyubiquitinated protein is 
processed in a stepwise fashion involving a series of three enzymes: Ubiquitin ligase 
E1, the ubiquitin activation enzyme, uses ATP hydrolysis to catalyze a thioester bond 
between E1 and the glycine residue of ubiquitin. After activation, the ubiquitin is 
transferred to the ubiquitin-conjugating enzyme E2. Next, E3 ubiquitin ligase proteins 
bind to the protein substrate. Finally, the polyubiquitinated protein is then 
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recognized by the proteasome and degraded [10, 11]. The removal of ubiquitin 
monomers or polyubiquitin chains from the substrate protein is catalyzed by 
deubiquitinating enzymes (DUBs); these enzymes counter the function of E3 
ubiquitin ligases [12]. Over 70 DUBs encoded in the human genome play roles in 
recycling of ubiquitin from the substrate proteins, protection from protein 
degradation by removing the ubiquitin tags, and also regulation of non-proteasomal 
functions such as DNA damage repair [13, 14]. 
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Figure 1.1 Ubiquitin Proteasome System 
A polyubiquitin chain is covalently linked to a protein substrate through a series of 
three enzymes: an E1, an E2, and an E3. This polyubiquitin chain is recognized by the 
proteasome, which degrades the protein to short peptides and releases free ubiquitin.  
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1.2 Proteasome Structure and Subtype 
1.2.1 Proteasome Structure 
As the final executioner of the UPS, the proteasome is responsible for the 
controlled degradation of substrate proteins modified with a polyubiquitin chain. The 
proteasome is large protein complex, approximately 2.4 MDa, and consisted of two 
main components, the 20S core proteasome particle and a 19S regulatory complex. 
The 19S regulatory complex harbors 18 subunits containing the components to 
remove the polyubiquitin chain for recycling of ubiquitin, unfold the protein, and 
control the access of substrate proteins to the proteolytic 20S core [15-19].  The 20S 
core itself has a molecular weight of approximately 700 kDa and is formed from four 
heptameric rings: two outer α-rings and two inner β-rings (Figure 1.2).   
The α-rings made from the α1-α7 subunits play an important role in regulating 
substrate entry into the 20S core for proteolysis. The inner two rings are also each 
made up of the β1-β7 subunits.  The 20S proteasome has three types of catalytically 
active subunits, the β1, β2, and β5 subunits located in the two inner beta rings [20]. 
These catalytically-active subunits utilize an N-terminal threonine residue for their 
catalytic activity, placing them in the N-terminal nucleophile hydrolase family. Each 
catalytic subunit is initially made with propeptides that protect the N-terminal 
threonine residue from acetylation and prevent premature proteolysis [21]. Removal 
of these propeptides occurs through an autocatalytic mechanism with the fully 
assembled proteasome, indicating that these subunits cannot degrade proteins prior 
to their proteasome incorporation [22-26]. When a substrate protein enters the core 
20S core particle, the active sites start cleaving the peptide bonds, generating peptide 
fragments ~3-22 amino acids in length [27,28]. Most of the products produced by the 
proteasome are then hydrolyzed by peptidases to single amino acids [29]. The 
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catalytically-active β1, β2, and β5 subunits also possess distinct substrate specificities. 
Structural and mutational studies revealed that the β5-subunit is responsible for 
chymotrypsin-like (CT-L) activity and cleaves peptide bonds preferentially after 
hydrophobic residues. The β1-subunit has caspase-like (C-L) activity cleaving the 
peptide bonds after acidic residues; and β2 cleaves after basic residues, consistent 
with trypsin-like (T-L) activity [30-34].  Together, these subunits cleave proteins into 
small peptides of unique and diverse sequences, which are especially important for 
antigen presentation and immune response [35]. 
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Figure 1.2. Structure of the 26S proteasome and the view of subunits of a β-ring  
26S proteasome consists of a 20S core particle with two 19S regulatory particles at 
either end. The 20S core particle is formed with four heptameric rings, two α-rings 
and two β-rings. Each β-ring contains three catalytically-active β-subunits (β1, β2, 
and β5). 
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1.2.2 The Immunoproteasome and Thymoproteasome 
Apart from the standard or also termed constitutive proteasome, there are 
subtypes of proteasomes having different structures: the immune proteasome and 
the thymoproteasome. A decade after the constitutive proteasome was discovered, 
another major subtype of the proteasome, the immunoproteasome was identified 
[36]. The immunoproteasome is predominant in immune cells such as monocytes and 
lymphocytes and is dramatically induced in non-immune tissues by proinflammatory 
cytokines such as interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) or viral 
infection [37]. Whereas the most common subtype of the proteasome, constitutive 
proteasome, comprises the catalytic subunits β1(Y, PSMB6), β2(Z, PSMB7), and β5(X, 
PSMB5), immunoproteasome differs mainly in incorporation of a distinct set of 
additional catalytic subunits in the 20S proteasome. The three catalytic immune 
subunits, β1i (LMP2, lower molecular weight protein 2, PSMB9), β2i (MECL-1, 
multicatalytic endopeptidase complex-like-1, PSMB10) and β5i (LMP7, PSMB8) 
subunits, are the homologues of the β1, β2, and β5 subunits, respectively, with 59-71% 
amino acid sequence identity to respective constitutive homologues [38]. The β1i, β2i, 
and β5i catalytic subunits are incorporated to 20S proteasomes in place of the β1, β2, 
and β5 subunits resulting in formation of the immunoproteasomes (Figure 1.3). 
The most recently discovered subtype of the proteasome is the 
thymoproteasome. In 2007, Murata et al. identified a previously unrecognized 
catalytic subunit called β5t expressed in cortical thymic epithelial cells [39]. The β5t 
subunit is the homolog of the β5 subunit with 50% amino acid sequence identity [38]. 
In cortical thymic epithelial cells, β5t subunit is incorporated with β1i and β2i subunit 
forming the specific subtype of the proteasome, thymoproteasome. 
Thymoproteasome plays a role in the positive selection of CD8+ T cells, acting as the 
safeguard against mature T cells deriving autoimmune response. Indeed, β5t -
deficient mice with lacking CD8+ thymocytes were not able to survive by influenza 
8 
 
virus infection [40, 41]. However, there is little data to show the exact functions of 
thymoproteasome in cancer or in non-cancer disease.   
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 Figure 1.3. Catalytic subunit compositions of the constitutive proteasome and 
the immunoproteasome 
The constitutive proteasome β-ring contains three catalytic β subunits β1, β2, and β5 
as well as four catalytically inactive β-subunits. The synthesis of immunoproteasome 
is induced by cytokine stimulations such as IFN-γ or TNF-α. The induced 
immunoproteasome catalytic subunits β1i, β2i, and β5i are incorporated into the 20S 
proteasome to form the 20S immunoproteasome. Catalytic subunits β1/ β1i, β2/ β2i, 
or β5/ β5i have caspase-like, trypsin-like, or chymotrypsin-like activity, respectively. 
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1.3 Proteasome Function 
The life cycle of all proteins starts from the synthesis at ribosomes to their 
degradation to peptides and further single amino acids. Protein degradation is the 
important step for cellular functions such as protein homeostasis, signal production, 
and cell proliferation. The proteasome located in the cytosol and the nucleus degrades 
more than 90% of cytosolic proteins by protecting cells from accumulation of harmful 
protein aggregates [42]. Proteasomes also play the major role in antigen presentation 
by production of peptides with hydrophobic C-terminal amino acids that bind with 
high affinity to major histocompatibility class I (MHC-I) receptors on the cell surface 
to control immune responses whereas another protease generates the correct N-
terminus [43]. Especially, the immunoproteasome catalytic subunits are known to 
produce the peptides with a hydrophobic or basic C-terminal amino acid but less 
acidic C-termini [44]. 
The immunoproteasome, beyond the antigen presentation, regulates oxidative 
stress, and cytokine production. The role of the immunoproteasome was defined on 
reducing the oxidized proteins under Interferon-induced oxidative stress to maintain 
cellular homeostasis [45]. More interestingly, previous studies showing β1i knock out 
mice displayed the significantly increase levels of oxidized proteins in the brain and 
retinal pigmented epithelial (RPE) cells were more sensitive to oxidative stress in 
double knock-out mice of β2i and β5i suggested that immunoproteasome are 
protective against oxidative stress and damage [46, 47]. 
Additional studies of β1i knockout mice showed that their cognitive function 
was quite similar comparted to control mice, but they had a higher body weight and 
displayed the greater motor function [48-50]. Martin. et al. suggested that the 
increased motor function observed in patients with Parkinson’s and Huntington’s 
disease may relate to changes in the expression levels of proteasome subunit 
expression in the brains of these patients [50]. More recent study showed β5i 
knockout altered the levels of cytokines in whole brain and the profiles of microglial 
cytokine production without impacting levels of Aβ or amyloid precursor protein 
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(APP). Notably, the production of the proinflammation cytokines such as TNF-α, IL-6, 
and IL-1β in isolated microglia was significantly reduced in cells lacking β5i [51]. 
In addition, the immunoproteasome (specifically β5i) has been shown to 
modulate pro-inflammatory cytokine production in human tissues (T-cells, B-cells, 
neutrophils, monocytes, etc) and thus considered as a promising therapeutic target 
for autoimmune diseases [52-57]. β5i/LMP7-selective inhibitors (ONX-0914, KZR-
616) are currently in early phase clinical development for the treatment of rheumatic 
diseases, such as lupus nephritis (LN). For β1i LMP2, there have been a few reports 
suggesting its involvement in processing of NF-κB precursors (p100/p105) and 
degradation of IκBα [58-60].  However, recent studies dispute the involvement of 
LMP2 in inflammatory responses showing using human peripheral blood 
mononuclear cells (PBMCs) reported no effect of LMP2 inhibition on cytokine 
secretion [56]. 
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1.4 Development of Proteasome Inhibitors 
To elucidate the functions of the proteasome in the cells, proteasome inhibitors 
were initially developed but it became evident that proteasome inhibitors may have 
therapeutic potential for diseases including cancer and inflammatory disease. Most 
of the proteasome inhibitors that have been developed are composed of a peptide 
sequence followed by a C-terminal warhead, pharmacophore, which interacts with 
the catalytic threonine residues of the proteasome’s active sites. The most of 
proteasome inhibitors can be classified by the unique warhead pharmacophore into 
five main classes; the peptide aldehydes, peptide boronates, β-lactones, peptide vinyl 
sulfones, and peptide epoxyketones (Figure 1.4). In this section, known proteasome 
inhibitors classified will be discussed. 
 
1.4.1 Peptide Aldehyde Inhibitors 
Peptide aldehydes were the first class of synthetic proteasome inhibitors to be 
developed. Since the catalytic activity of the proteasome were initially thought to be 
similar to that of serine and cysteine protease, the first type of proteasome inhibitors 
were developed by using a C-terminal aldehyde, Z-LLF-CHO, Ac-LLnL-CHO, and Ac-
LLM-CHO [61]. Co-crystallization of a peptide aldehyde inhibitor with the yeast 
proteasome showed aldehyde group of the inhibitor binds the active sites of the 
proteasome reversibly by producing hemiacetal adducts with the threonine residue 
of the catalytic site [30]. While a number of studies have used the peptide aldehyde 
inhibitors, further development of this class of proteasome inhibitors has been 
limited because of their off-target inhibition of cysteine and serine protease. forming 
hemiacetal adducts with their catalytic threonine residues [30, 33]. In this 
dissertation work, MG132 (Z-LLL-CHO, shown in Figure 1.4.) was used as a 
representative of peptide aldehyde inhibitor. 
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1.4.2 Peptide Boronate Inhibitors 
Peptide boronates were also initially developted to inhibit serine protease. 
However, peptide boronates harbor the high affinity for the active site of the 
proteasome by interaction between a boronate hydroxyl group and the N-terminal 
amino group of the threonine residue of the proteasome active site. By that means, 
peptide boronates can achieve better potency and high selectivity to the proteasome 
over the serine protease. In the meantime, Adam et al. reported peptides boronates 
such as MG262 which is the boronate analog of MG132 with better potency and higher 
selectivity compared to the inhibitors with aldehyde pharmacophore in 1998 [62]. 
Further medicinal chemistry efforts with peptide boronates led to the development 
of the FDA-approved proteasome inhibitor drugs, bortezomib and ixazomib (Figure 
1.4). Bortezomib and ixazomib will be discussed in detail below. 
 
1.4.3 β- Lactone Inhibitors 
Lactacystin was the first reported natural product of proteasome inhibitor 
with a non-peptide backbone (Figure 1.4). In 1995, Fenteany et al. found lactacystin 
bound to the threonine residue of the proteasome catalytic β5 subunit. Later, it was 
demonstrated lactacystin, converting to active form, clasto-lactacysistin β-lactone, at 
pH 8 from inactive itself, irreversibly inhibits CT-L activity predominantly and trpsin-
like (T-L) and Caspase-like (C-L) activities at much slower rates [63].  Although 
lactacystin also found to be more specific to proteasome than the peptide aldehyde 
inhibitors, later works suggested β- Lactones also bind to some serine proteases [64, 
65]. Besides this, the unstability of β- Lactones at neutral pH, and highly complex 
synthesis were considered as limitations of β- Lactones.  Marizomib, known as 
salinosporamide A or NPI-0052, is a second natural product β-lactone, is currently in 
clinical development [66]. Notably, Di et al. observed that orally dosed marizomib 
significantly reduced the proteasome activity in pre-fontal cortex of healthy 
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cynomolgus monkeys, postulating the activity of marizomib to cross the blood-brain 
barrier [67]. 
 
1.4.4 Peptide Vinyl Sulfone Inhibitors 
Peptide vinyl sulfones are another early class of proteasome inhibitors. 
Initially, Z-LLL-VS displayed the activity to target all three proteasome catalytic 
activities in purified proteasome and in cells. Bogyo et el. showed the vinyl sulfone 
pharmacophore binds to the hydroxyl group of the threonine residue, giving rise to 
irreversible-binding between proteasome inhibitors to the catalytic residue [68] 
(Figure 1.4). In line with this, this class of proteasome inhibitors labeled with a 
radioisotope, biotin, or fluorescent groups were utilized to understand the 
relationships between the peptide sequence of the inhibitor and its subunit binding 
specificities [69-71]. However, since the peptide vinyl sulfones were also initially 
developed as cysteine protease inhibitors, the use of vinyl sulfones is limited. 
 
1.4.5 Peptide Epoxyketone Inhibitors 
Another important class of natural product proteasome inhibitors, 
eponemycin and epoxyketone, was reported in 1999. Both eponemycin and 
epoxyketone are consisted of a peptide backbone with and N-acyl group and a C-
terminal α’,β’-epoxyketone moiety (Figure 1.4).  Eponemycin isolated from a 
Streptomyces strain was later shown to bind to β1i, β5i and β5 subunits of the 
proteasome whereas epoxyketone isolated from a Actinomycete strain was found to 
bind to β2, β5, β2i, and β5 by a group under Dr. Craig Crews [72, 73]. Their further 
studies showed epoxomicin primarily targets the CT-L acitivity of bovine 
proteasomes in an irreversible fashion. In 2000 Groll et al. reported the formation of 
a 6-membered morpholino ring between the catalytically active threoine residue and 
the inhibitor by X-ray crystallographic study of epoxomicin bound to the proteasome, 
giving rise to high specificity for the proteasome over other proteases such as serine 
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and cysteine proteases [74]. However, in 2016, Schrader et al. revealed a 7-membered 
1,4- oxazepane ring, instead of a 6-membered morpholino ring between the threonine 
residue and the epoxyketone inhibitors using high-resolution X-ray structures of 
human 20S proteasome with three different epoxyketone inhibitors [75]. A notable 
peptide epoxyketone inhibitor, of special interest, Carfilzomib, is the second 
proteasome inhibitor to receive FDA approval for use as an anticancer agent [76].  
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Figure 1.4. Representative members of the five major classes of proteasome 
inhibitors 
A. Peptide aldehydes. A synthetic peptide aldehyde inhibitor MG-132 is shown. B. 
Peptide boronates. FDA-approved bortezomib and ixazomib are shown. C. β-lactone. 
The natural product lactacystin is shown. D. Peptide vinyl sulfone. Early proteasome 
inhibitor Z-LLL-VS is shown. E. Peptide epoxyketones. The natural product 
epoxomicin and FDA-approved carfilzomib are shown.  
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1.4.6 Subunit-Selective Proteasome Inhibitors 
a. β5-selective inhibitors 
PR-825 is the β5-seletive peptide expoxyketone inhibitor (Figure 1.5). This 
compound was used to distinguish the effects of selective β5-inhibition versus β5i 
inhibition on the production of pro-inflammatory cytokines in activated peripheral 
blood mononuclear cells (PBMCs) and an animal model of multiple sclerosis [52, 77]. 
PR-893, also known as CPSI (Constitutive proteasome selective inhibitor), was 
another β5-seletive peptide expoxyketone inhibitor. ProCISE assay showed this 
compound is highly selective for β5 over β5i (~21 fold) or β1i (~13 fold). PR-893 was 
utilized to examine the cellular effect of selective- β5 inhibition in cells, showing that 
inhibition of β5 subunit alone was not sufficient to induce cytotoxicity in hematologic 
cancer cells. Furthermore, selectively inhibiting β5 with PR-893 did not block 
production of IFN-α by bone marrow cells [78, 79]. 
 
b. β5i-selective inhibitors 
The first β5i-selective inhibitor to be reported was ONX 0914, also referred as 
PR-957 (Figure 1.5). The tripeptide epoxyketone ONX 0914 showed a 20- and 40- fold 
selectivity for β5i over β1i or β5, respectively in human leukemia cell line MOLT-4 
cells. Interestingly, ONX 0914 has shown to block the production of pro-inflammatory 
cytokines in PBMCs as well as T-cell activation and differentiation and to attenuate 
progression of experimental arthritis in mouse model, indicating a role of β5i during 
inflammation [52]. This supports the futher investigations to the potential 
therapeutic benefits of β5i inhibitors in treating autoimmune diseases are going [80]. 
The second β5i-selective epoxyketone inhibitor to be reported was IPSI 
(immunoproteasome-selective inhibitor), also known later as PR-924 [79] (Figure 
1.5). ProCISE assay showed IPSI was highly potent for β5i (IC50 of 22 nM against β5i) 
and 132-fold selectivite for β5i over β5. Later, there were a few studies reporting  PR-
924 inhibited cell growth and induce apoptosis in multiple myeloma cells whereas 
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PBMCs were not affected and further it exerted antitumor activity in mouse xenograft 
models [81].  
 
c. β1i-selective inhibitors 
As described above, the peptide epoxyketone natural products eponemycin 
and epoxomicin exerted a preference for β1i over other subunits. This gives rise for 
our lab to examine the the structure-activity relationship (SAR) for β1i inhibition 
using eponemycin analogues. Further medicinal chemistry efforts yielded the first 
immunosubunit-selective inhibitor, β1i-selective peptide epoxyketone inhibitor UK 
101, to be reported by our group [82] (Figure 1.5). Our group reported UK101 was 
more cytotoxic to cancer cells highly expressing β1i than immunosubunit- deficient 
cells, suggesting β1i may play a role in regulating cell-growth in cancer cells 
abundantly expressing β1i. Later, Wehenkel et al. found that UK101 significantly 
reduced tumor growth in a mouse xenograft model of prostate cancer [83]. Later, 
UK101 was also reported to be highly selective for β1i over β1 (144-fold), but less 
selective for β1i over β5 (10-fold) [84].  
Most recently, proteasome activity assay using subunit-selective fluorogenic 
peptide substrates showed the previously reported caspase-like inhibitor YU 102 
(Ac-GPFL-epoxyketone) had high selectivity for β1i over β5 (> 100 fold) (submitted 
data by our group).  
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Figure 1.5. Representative of subunit-selective proteasome inhibitors  
A. β5-selective inhibitor. The peptide epoxyketone inhibitor PR-825 is shown. B. β5i-
selective inhibitors. The peptide epoxyketone ONX0914 (PR-957) and IPSI (PR-924) 
are shown. C. β1i-selective inhibitor. The epoxyketone inhibitor UK101 is shown. 
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1.5 The FDA-Approved Proteasome Inhibitors for MM 
1.5.1 Bortezomib (Velcade®) 
The first proteasome inhibitor to receive FDA approval was Bortezomib (Btz), 
formerly known as PS-341 and now marketed as Velcade® [85]. Structurally, 
bortezomib is a dipeptide boronate, mainly targets the both β5 and β5i subunits 
specifically and reversibly [86-88]. It has also been shown to target β1 and β1i with 
lower affinity [89, 90].  
As previously described in chapter 2.4.1, considerable effort had been put 
forth to develop the peptide boronates with the improved selectivity for proteasome 
activity over serine proteases, leading to yield the derivatives of peptide boronates 
with the dramatically enhanced selectivity for the CT-L activity of the proteasome and 
the improved inhibitory potency. Meaningful results from collaboration work 
between ProScript and scientists at the National Cancer Institute (NCI) were 
published in 1999. The peptide boron ester PS-341 showed the most potent 
proteasome inhibition and significant cytotoxicity in the National Cancer Institute 
(NCI) panel of 60 cancer cell lines for assessing their anti-cancer activities among 13 
derivatives of the peptide boronates.  Following these results, PS-341 was tested 
against mice bearing tumor xenografts. This study showed that a single i.v. injection 
of 0.3 mg/kg PS-341 could significantly inhibit proteasome activity in white blood 
cells and in PC-3 tumor cells. Four direct injections of 1 mg/kg PS-341 into PC-3 
tumors on a daily or weekly schedule significantly reduced tumor volume as 
compared to vehicle [62].   
These significant results from preclinical trials of PS-341 led this compound 
into clinical trials in 2000 for further investigation of PS-341 as a potential anti-cancer 
reagent. Adams et al. reported in phase I trials PS-341 was well tolerated by patients 
in general, but with toxicities such as thrombocytopenia, fatigue, and peripheral 
neuropathy. Anecdotal reports of efficacy of the PS-341in non-small cell lung cancer, 
melanoma, and multiple myeloma were also noted in the study [91].  During its 
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clinical development at Millenium Pharmaceuticals, PS-341 received the 
nonproprietary name bortezomib and was finally marketed under the brand name 
Velcade®. In phase II clinical trials, bortezomib also demonstrated notable anti-
cancer efficacy in newly diagnosed and relapsed/refractory multiple myeloma 
patients when administered in combination with other reagents including 
thalidomide, dexamethasone, and doxorubicin [92-94].  
Based on promising clinical trial results, bortezomib was received the FDA 
approval in 2003 for the treatment of relapsed and refractory multiple myeloma [95]. 
Following the initial approval, the FDA expanded the bortezomib (Velcade) label to 
allow for previously untreated patients with multiple myeloma and mantle cell 
lymphoma [96, 97]. 
 
1.5.2 Carfilzomib (Kyprolis®) 
Carfilzomib, formerly called PR-171 and now marketed as Kyprolis®, is the 
second proteasome inhibitor to be FDA-approved in 2012 for treating relapsed or 
refractory multiple myeloma. In a 2007 publication by Demo et al., carfilzomib 
inhibited the CT-L activity of the proteasome more selectively compared to 
bortezomib also slightly targeting β1 [86, 98]. Another remarkable difference 
between carfilzomib and bortezomib is the proteasome specificity derived from the 
unique interaction of the epoxyketone pharmacophore and the N-terminal Threonine 
residues of the catalytic subunits of the proteasome. The proteasome specificity led 
to lower in vivo toxicity of carfilzomib relative to that of bortezomib and lower 
peripheral neuropathy, which is an off-target side effects of bortezomib, in 
carfilzomib-treated patients than bortezomib-treated patients [86, 99-103]. 
Furthermore, in comparison with bortezomib, the irreversible binding mechanism of 
the carfilzomib also facilitates a more sustained proteasome inhibition following a 
single exposure [86], suggesting carfilzomib exerts enhanced anticancer efficacy over 
bortezomib. 
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As previously described in chapter 2.4.5, the design of carfilzomib was begun 
from the natural product epoxomicin which was found to have proteasome inhibition 
in cells [73]. Traditional medicinal chemistry efforts from the Crews lab to optimize 
epoxomicin for anticancer activity led to development of potent YU101 derivatives. 
Following the successful clinical trials of bortezomib, Proteolix Inc. was established 
to develop YU101 as an anticancer therapeutic based on the great potency of YU101. 
Further medicinal chemistry efforts at Proteolix resulted in optimization of YU101 to 
improve poor water solubility (< 1 µg/mL) of YU101, yielding the lead compound PR-
171, with the modified to the N-cap moiety of YU101 [86]. The potent anti-cancer 
efficacy of PR-171 was further verified in mouse xenograft models. Notably, PR-171 
exerted its activity in multiple myeloma cell lines and tumor cells derived from 
patients who did not respond to bortezomib and cells resistant to conventional 
chemotherapeutics.  
Based on these promising results of PR-171, Proteolix began phase I clinical 
trials of PR-171 with the generic name carfilzomib. Two phases I dose-escalation 
trials of single-agent carfilzomib were conducted in patients with relapsed or 
refractory hematologic malignancies to determine its safety and efficacy in patients 
with hematologic malignancies. Results from these studies established a dosing 
schedule of carfilzomib i.v. infusions, a consecutive-day, twice weekly at dose up to 
27 mg/m3 [101]. During the two trials, carfilzomib was well tolerated by patients and 
the objective response rate (ORR) was 16.7% and the median duration of response 
was 7.2 months for the ORR population [100, 101], giving rise to additional phase 2 
trials to evaluate the activity of single-agent carfilzomib i.v. infusions at 20 or 27 
mg/m3 in patients with relapsed or refractory multiple myeloma patients who did not 
respond to prior therapies such as bortezomib and a single immunomodulatory agent 
(e.g. thalidomide and lenalidomide). In 2010, Siegel at al. reported the ORR was 24% 
and the median duration of response was 7.4 months [104]. In 2009, Onyx 
Pharmaceuticals acquired Proteolix for clinical development of carfilzomib and 
presented additional safety data from a total of 768 patients treated in phase I and II 
studies. Together, carfilzomib was granted accelerated FDA approval on July 20th, 
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2012 [76]. From the phase III trial to further confirm the drug’s efficacy and safety, 
the clinical benefits of carfilzomib were examined in combination with the 
immunomodulatory agent lenalidomide and high-dose dexamethasone in patients 
with relapsed and refractory multiple myeloma. Results showed combination 
treatment of carfilzomib with the lenalidomide and dexamethasone had superior 
activity in comparison to only lenalidomide and dexamethasone, without carfilzomib 
[105]. More recently, ENDEAVOR the phase III trial study to compare combination of 
carfilzomib and dexamethasone versus that of bortezomib and dexamethasone in 
relapsed or refractory multiple myeloma patients, supporting the safety of higher 
doses of carfilzomib and better efficacy in those patients: the median progression free 
survival (PFS) in the carfilzomib group was 18.7 months, the bortezomib groups 
median PFS of 9.4 months [106].  
 
1.5.3 Ixazomib (Ninlaro®) 
Ixazomib, previously known as MLN9708 and now marketed as Ninlaro®, is 
the third proteasome inhibitor to be received the FDA approval in 2015 for the 
treatment of relapse multiple myeloma patients. Ixazomib is the first orally 
administered proteasome inhibitor. Structurally, Ixazomib is a N-capped dipeptide 
boronate and the boronate pharmacophore. Ixazomib can be formed from the 
hydrolized prodrug ixazomib citrate in aqueous solution or plasma, giving rise to the 
improved oral bioavailability compared to bortezomib and carfilzomib [107]. 
Ixazomib has a similar selectivity profile of the proteasome subunit to that of 
bortezomib, preferentially inhibiting β5 reversibly, and to a lesser extent, β1 catalytic 
subunit [107]. Chauhan et al. also reported that ixazomib inhibited the CT-L activity 
more strongly and displayed anticancer activity in multiple myeloma cells, even in 
bortezomib resistant multiple myeloma cells. Moreover, ixazomib exerted greater 
antitumor efficacy in xenograft mouse models of multiple myeloma, lymphoma, and 
solid cancers, supporting ixazomib’s superior anti-cancer activity compared to 
bortezomib [107, 108].  
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In clinical trials, the median time of progression free survival of patients with 
relapsed or refractory myeloma in combination therapy of ixazomib with 
dexamethasone and lenalidomide was significantly prolonged (20.6 months in 
ixazomib-treated group versus 14.7% in the control group) [109, 110]. Notably, 
ixazomib had the improved toxicity profile despite the same pharmacophore as 
bortezomib [111]. Taken together, FDA approval was granted to ixazomib in 2015 for 
use in combination with dexamethasone and lenalidomide in treating multiple 
myeloma in patients who have received at least one prior therapy [112].  
1.6 Resistance to Proteasome Inhibitors 
 As previously discussed, the FDA approvals of proteasome inhibitors, 
bortezomib, carfilzomib, and ixazomib in 2003, 2012, and 2015, respectively, have 
transformed treatment paradigm for patients with newly diagnosed and refractory 
multiple myeloma. However, multiple myeloma remains incurable with an expected 
median survival of 7-8 years [113, 114]. The biggest challenge of the use in treatment 
of multiple myeloma patients is drug resistance. Although the response rates of 
bortezomib and carfilzomib were increased up to ~70-90% when combined with 
other drugs including lenalidomide, all patients eventually develop resistance to 
therapy and have a dismal prognosis once resistance emerges [115]. In order to 
understand the mechanisms of proteasome inhibitor resistance in patients, extensive 
preclinical efforts have been undertaken. Although the exact resistance mechanisms 
of clinical proteasome inhibitors are still unknown, several preclinical studies 
reported the candidate resistant mechanisms to proteasome inhibitors. 
 
1.6.1 Bortezomib resistance 
Over the last decade many potential mechanisms, including proteasome-
dependent and proteasome-independent mechanisms, have been studied for 
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bortezomib resistance. Mainly reported mechanisms for bortezomib resistance were 
mutations in the PSMB5 gene and upregulation of constitutive catalytic subunits. 
Using the established bortezomib resistant lurkat cell line model developed by 
adapting cells to increasing concentration of bortezomib, Lu et el. and Oerlemans et 
al. reported the mechanisms responsible for bortezomib resistance in cancer cells. 
The bortezomib resistant- lurkat cell line or -THP-1 cell line containing 
overexpressed PSMB5 gene encoding the β5 catalytic subunit of the proteasome. 
Moreover, CT-L activity and the expression levels of β5 catalytic subunit were 
increased in these cell lines, supporting the β5 catalytic subunit is the key component 
for bortezomib resistance [116, 117]. Indeed, siRNA-mediated silencing of the PSMB5 
gene resulted in sensitization of bortezomib-resistant THP-1 cells to bortezomib. In 
such models, point mutations (Met45, Ala49Thr, and Cys52) in the PSMB5 gene 
affecting the proteasomal inhibitory activity of bortezomib were also identified. Since 
the location of those point mutations was highly conserved S1 binding pocket of β5, 
it was postulated that mutations in the PSMB5 gene interfered the binding of 
bortezomib to β5, thus affecting the cytotoxic effects of bortezomib in cells. Although 
these preclinical findings suggested the potential bortezomib-resistant mechanism in 
several cell line models, only one case study has identified PSMB5 gene mutations in 
a patient who had treated with bortezomib [118-120].  
Recent study has focused on the potential role of the unfolded protein response 
(URP) in resistance to proteasome inhibitors. The UPR is a stress response pathway 
and causes cell apoptosis when it is activated. One of main transcription factors 
involved in the UPR signaling, X-box binding protein 1 (Xbp-1), is known to be highly 
expressed in myelomas compared other cancer types, suggesting Xbp-1 is 
indispensable for multiple myeloma pathogenesis such as development of plasma 
cells [121, 122]. While it has been reported that proteasome inhibitors can both 
induce the UPR and inhibit Xbp-1, the roles of the UPR and Xbp-1 in proteasome 
inhibitor resistance was not explored in detail until early 2000’s [123]. In 2012 Ling 
et al. reported response of myeloma to bortezomib is correlated to the Xbp-1 and the 
study showed the downregulated Xbp-1 expression in bortezomib resistant multiple 
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myeloma cells, suggesting low Xbp-1 expression is associated with lower bortezomib 
sensitivity [124]. In 2016, Nikesitch also found the significant role of Xbp-1 in 
determination of the sensitivity to bortezomib in hematological cell lines and primary 
multiple myeloma samples [125]. In contrast to 2012 Ling et al.’s study, Leung-
Hagesteijn et al. found that Xbp-1 silenced mediated bortezomib resistance in 
multiple myeloma cell lines and identified two Xbp-1 mutations Xbp-1 L178I and 
P326R in bortezomib-resistant multiple myeloma.  Multiple myeloma cell lines with 
Xbp-1-silenced or Xbp-1 mutations with lower protein load and the UPR activation 
may exhibit a survival advantage against proteasome inhibition induced cytotoxicity 
[126]. In line with this, high Xbp-1 expression can be a prognostic marker of clinical 
outcome in multiple myeloma patients who treated with bortezomib [127]. While 
Xbp-1 may play a key role in the sensitivity to multiple myeloma to bortezomib, it is 
still unknown whether resistance of other cancer types to PIs are also related to the 
function of Xbp-1. 
 
1.6.2 Carfilzomib resistance 
The studies conducted to date have mainly focused on elucidating bortezomib 
resistant mechanism, and there are only a few have explored resistant mechanisms 
against carfilzomib in cancers. 
P-glycoprotein (P-gp), also termed as MDR1, is a transporter that extrudes a wide 
range of substrates out of the cells in an ATP-dependent manner and it is well 
documented that it can mediate cancer resistance to other anti-myeloma agents such 
as doxorubicin, paclitaxel, and vincristine [128-131]. Verbrugge et al. found the 
several drug efflux transporters have involved in the sensitivities to proteasome 
inhibitors such as bortezomib, carfilzomib, ONX 0912, ONX 0914 in carfilzomib/ONX 
0914 cross-resistant cancer cells [132]. In this study, overexpression of P-gp was 
observed in carfilzomib resistant cells compared to in the its parental cells. Moreover, 
the use of reversin 121, a P-gp inhibitor, restored the sensitivity to proteasome 
inhibitors in both CEM/VLB cells and peripheral blood mononuclear cells, suggesting 
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P-gp plays a significant portion of resistance mechanism in cancers against 
epoxyketone proteasome inhibitors. Consistent with these findings, our group also 
found that the expression levels of P-gp was upregulated in carfilzomib resistant H23 
lung and DLD-1 colon cancer cells and P-gp inhibition by verapamil altered 
carfilzomib sensitivity to near that of the parental cell lines [133]. More interestingly, 
a 2016 publication showed the induced gene expression of P-gp in primary cells 
derived from multiple myeloma patients who did not respond to carfilzomib therapy 
[134]. Using multiple myeloma cells isolated from patients during carilzomib therapy, 
Besse et al. also showed that ABCB1 gene expression was increased and gene deletion 
resulted in sensitization of carfilzomib resistant AMO cells to carfilzomib [135]. Since 
only these two studies showed the clinical evidence of P-gp mediated resistance to 
proteasome inhibitors, further validations of this mechanism are important to 
confirm their relevance in the clinic and to develop the therapeutic strategies 
overcoming proteasome inhibitors resistance in cancers. 
 
1.7 Alzheimer’s Disease  
Alzheimer’s disease (AD) is the most common form of dementia in the elderly, 
accounting for around 60% of all dementia cases [136]. An estimated 5.7 million 
Americans of all ages are living with AD in 2018, and the proportion of elderly people 
in the population has been increasing steadily, thus the burden of the disease is 
expected to become greater over years. AD is a neurodegenerative disorder with a 
mean duration of around 8.5 years between clinical symptoms and death.  
Alzheimer’s disease was first described by Alois Alzheimer. In 1906, a 
psychiatrist and neuropathologist Alois Alzheimer first reported “A severe disease 
process of the cerebral cortex” to the 37th Meeting of South-West German 
Psychiatrists in Tubingen, Germany. At the meeting, Alzheimer described an unusual 
case, a 50-year-old woman Auguste D. with memory impairment, psychosocial 
incompetence and disorientation until her death 5 years later. While the unfamiliar 
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notion that a “mental” disorder like presenile dementia could be due to “physical” 
aberrations was not easily accepted at the time, nevertheless, the disorder would be 
named in 1910 after Alois Alzheimer by his mentor, Emil Kraepelin. Alois Alzheimer 
also presented the observation of the neuropathological lesions, neurofibrillary 
tangles in the brain of her at autopsy in 1911 [137, 138]. Until the late 1960’s, 
Alzheimer’s disease itself was not considered as a disease separated from dementia. 
Kay et al. identified AD was different from normal aging symptoms in 1964 and it was 
reported there was a relationship between cognitive dysfunction and the hallmarks 
of the disease such as neurofibrillary tangles and neuropathological lesions in a 1968 
publication by Blessed et al. [139, 140]. In 1981, Heston et al. first reported that 
relatives of 125 subjects who had autopsy-confirmed AD exhibited a significant 
excess of dementing illness consistent with genetic transmission [141]. Later study 
also identified mutations involved in hereditary forms of AD in 1996 [142]. These 
findings supported AD may be no longer considered as aging but should be diagnosed 
differently from other forms of dementia.  
According to most sources, AD is defined to consist of irreversible memory 
loss, and deterioration of language, judgement, confusion with time or place, and 
trouble understanding visual images, progressing over 10 to 15 years. Brain regions, 
particularly the neocortex and hippocampus, are associated with higher mental 
functions, are most affected by the characteristic pathology of Alzheimer’s disease. 
Pathologically, AD is characterized by the accumulation of extracellular amyloid 
plaques in senile plaques made by the amyloid-beta protein and intracellular 
formation of neurofibrillary tangles which are aggregates of hyperphosphorylated 
tau protein, and the loss of neuronal synapses and pyramidal neurons. These changes 
develop the typical symptomology of Alzheimer’s disease [143, 144].  
Amyloid precursor protein (APP) is cleaved by three types of proteases, α-, β- 
and γ-secretases. Amyloid-beta (Aβ) is generated when the APP is cleaved by β 
secretase and then by γ secretase complex. β secretase cleaves APP at the bond 
between Met671 and Asp672 (β-site) and γ secretase cleaves at the site between 711-
713 amino acid, resulting in Aβ1-40 or Aβ1-42. Aβ1-42 is mainly found in the amyloid 
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plaques, a hallmark of AD, while Aβ1-40 also found in the plaque is predominantly 
involved in the brain vessels which is known as cerebral amyloid angiopathy. Since α 
secretase cleaves within the Aβ sequence of APP, cleavage of APP by combination of  
α secretase and γ secretase does not generate Aβ [145].  
Neurofibrillary tangles (NFTs), are aggregates of tau. Tau protein found in 
cytosol, axons, and neurons is the member of microtubule-associated proteins family. 
Blennow et al. suggested tau proteins might be synthesized in glial cells, mostly in 
pathological situations [146]. Microtubule-associated proteins regulates the stability 
of axon microtubules by promoting polymerization and binding with tubulin, 
resulting in suppression of their dephosphorylation. Phosphorylation of tau can occur 
at 30 different sites and hyper-phosphorylation of tau causes self-assemble into 
tangles and then accumulation of tau aggregates, thereby, leading the loss of axonal 
or dendritic transport in diseases [147-149]. 
 
1.8 Causal Theories of Alzheimer’s Disease 
Over the past two decades, a considerable research effort has been directed 
towards discovering the cause of Alzheimer's disease. To develop safe and effective 
pharmacological treatments, it is important to acknowledge that multiple causal 
theories for AD have been proposed. A few of these hypotheses are discussed briefly 
in this section. 
 
1.8.1 Cholinergic theory 
Martorana et al. reported a theory pertaining to the cause of AD, cholinergic 
hypothesis based on data showing AD brains expressed lower levels of a 
neurotransmitter acetylcholine in the brain compared to non-demented elderly [150].  
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Extensive efforts in discovering and characterizing the most important 
neurotransmitters and their receptors in the brain underlay specific nervous 
connections with brain functions, giving rise to establish the idea that altered function 
of neurotransmitter systems was associated with neuropathology. In a 1976 
publication, a specific cholinergic deficit was consistently identified from a forebrain 
to hippocampus and the cortex from AD patients [151]. Moreover, the activity of 
choline acetyltransferase, the enzyme for the synthesis of acetylcholine, was reduced 
in pathological samples from the hippocampus and cortex of the patients with AD. 
Based on these significant observations, Bartus et al. first stated the cholinergic 
hypothesis of age-related cognitive dysfunctions and dementia [152]. In addition, the 
1986 Nobel prize was awarded to Rita Levi Montalcini and Stanley Cohen for the 
discovery of nerve growth factor, leading the interest of neuronal survival factors in 
Alzeheimer’s disease. Taken all together, several drugs targeting cholinergic 
transmission were introduced for treatment of AD patients [153]. Four 
cholinesterase inhibitors, tacrine, donepezil, rivastigmine and galantamine, have 
received approval by FDA and have been widely used for years in many countries, in 
particular for patients who were diagnosed with mild and intermediate forms of AD. 
Reduction of cholinesterase resulted in retaining acetylcholine in the brain. Though 
the therapeutic options available on the market target the cholinergic system, the 
strategies have been failed to delay disease progression.  
 
1.8.2 Amyloid theory 
Amyloid hypothesis is the most heavily investigated theory for the cause of AD 
over 25 years [154-156]. The importance of amyloid was not the prevailed idea in a 
field of AD and Alzheimer’s researchers were considering the cholinergic hypothesis 
in the 1980s and assumed that a decline in the neurotransmitter acetylcholine is a 
cause of the disease at that time. Dennis Selkoe who is now a major proponent of 
amyloid hypothesis was not interested in acetylcholine at the time. After he met 
George Glenner who initially identified and biochemically characterized Aβ, Selkoe 
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moved his research to amyloid field from studying tau protein and built multiple 
findings from genetic, molecular, biochemical, and neuropathological studies of 
amyloid. Kang et al. reported the discovery of genetic mutations of APP in AD [157]. 
These mutations in APP/Presenilin are closely linked to the Aβ production process, 
providing a rational for the idea that Aβ production and Aβ amyloid fibril formation 
represent the central pathogenic cause of AD. In 1992, it was hypothesized by Seiko 
et al. that Aβ aggregation was the initiating factor in AD progression since the genetic 
links to AD all led to an increase in Aβ protein rather than tangles [158]. 
While Aβs excised from APP by β- and γ-secretase are released outside the cell and 
then are degraded in normal subject, degradation of Aβ is decreased and Aβ peptides 
are accumulated in the aged subject. In the brain of normal subject, the concentration 
of the Aβ peptide is regulated by following mechanisms: the Aβ peptide generation 
from APP, influx into the brain across the blood-brain barrier (BBB), clearance from 
the brain, and enzymatic degradation within brain [159-161]. Thereby, impairment 
of these regulatory mechanisms could result in the accumulation and deposition of 
excessive amounts of the Aβ peptide in the brain of AD patients. This amyloid 
hypothesis states that an increase in Aβ aggregation either from decreased clearance 
or increased production, leads to microglial and astrocytic activation, altered 
neuronal ionic homeostasis, altered kinase and phosphatase activity which increases 
phosphorylation of tau leading to tangle formation, leading to neuronal cell death and 
neurodegeneration. Thus, drugs that remove the amyloid should slow the 
progression of AD. Yet all drugs targeting amyloid, including solanezumab, 
bapineuzumab, and gantenerumab, have failed to reduce cognitive dysfunctions in 
phase III clinical trials and another antibody, ponezumab also failed after phase II 
[162-165]. These results have led scientists to become increasingly skeptical of the 
amyloid hypothesis and explore other potential pathogeneses of AD. 
 
 
32 
 
1.8.3 Tau theory 
As discussed before, the discovery of neurofibrillary tangles (NFTs) by Alois 
Alzheimer in the brains of patients with the neurodegenerative disorder named after 
him (Alzeimer’s disease) provided the basis for many studies to elucidate the 
molecular, cellular and genetic features of this disease more than a century ago. 
However, the discovery that the protein components of NFTs and the paired helical 
filaments (PHFs) were hyperphosphorylated forms of tau was achieved only during 
the 1980s. In 1986, Kosik et al. discovered that the NFTs in the brains of AD patients 
are composed of phosphorylated tau proteins [166].  Microtubule-Associated Protein 
Tau (MAPT) stabilizes microtubules and can undergo post-translational 
modifications such as phosphorylation. When tau is hyperphosphorylated, it 
dissociates from microtubules and aggregates into paired helical filaments (PHFs) 
and NFTs. The tau hypothesis speculates that tau tangle pathology precedes Aβ 
plaque formation and that tau phosphorylation and aggregation is the primary cause 
of neurodegeneration in AD. Tau phosphorylation reduces its ability to promote 
assembly of microtubule, giving rise to neurodegeneration through synaptic 
disruptions and neuronal loss [167, 168]. Furthermore, the NFT can cause neuronal 
impairment and death.  
While the amyloid hypothesis suggests that tau aggregation occurs 
downstream of Aβ aggregation, tau tangles can be detected in the brains of patients 
with very mild dementia and no Aβ pathology [169]. Tau pathology also correlates 
more closely with AD progression and severity than Aβ plaque load does [167, 170]. 
Tau hypothesis-based strategies have shown some promising results and there are 
currently seven anti-tau therapies in phase II trials [171]. However, anti-tau therapies 
have also failed in phase III clinical trials. Tau phosphorylation was facilitated by a 
protein kinase, glycogen synthase kinase 3 beta (GSK-3β), which is an attractive 
target for anti-tau therapies. GSK-3β inhibitors are arguably in the most advanced 
stages of clinical development for AD. Among the various drugs that are currently 
being investigated, tideglusib, an irreversible inhibitor of GSK3-β, has recently 
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completed phase II trials yet did not show significant clinical improvement in a phase 
II trial [172]. 
 
 
1.8.4 Neuroinflammation theory 
Since the late 1980s, several studies have shown that the chronic inflammation, 
seen in many diseases of the elderly, was found in the brain of AD patients and may 
even to initiate the recognized pathology. In 1990, McGeer et al. reported that 
exposure to anti-inflammatory drugs, known as non-steroidal anti-inflammatory 
drugs (NSAIDs), lowered the risk of AD. In addition, it was reported that NSAID 
delayed the progress of cognitive dysfunctions in 1995, suggesting that inflammation 
plays some roles in the disease and targeting inflammation may be used for treatment 
of degenerative brain disorder [173, 174]. Furthermore, new hypothesis suggesting 
amyloid peptide is involved in immunity also supports the contribution of 
inflammation in AD [175, 176]. Additionally, a common risk factor for the disease is 
brain injury, suggesting that chronic inflammation could initiate or at least partake in 
the course of AD [177].  
It has long been thought that the brain was immunologically privileged with 
no resident or infiltrating immune cells; however, it is now considered that the cells 
of the brain are contributing to neuroinflammatory responses. The glial cells of the 
brain (astrocytes, microglia, oligodendrocytes, and pericytes) are involved an 
inflammatory response, but the main regulator of inflammation in the brain is the 
microglia cell [178]. Microglial cells make up ~12% of brain cells and are generally in 
a resting state (termed inactive or less active state). It is now thought that yolk-sac 
derived fetal macrophages are the precursors for microglia while originally thought 
to be derived from the macrophage cell line. Tumor necrosis factor alpha (TNF-α) or 
interferon gamma (IFN-γ) stimulates macrophages to release several pro-
inflammatory cytokines and to produce reactive oxygen species [179-181].  This 
proinflammatory state, has high microbicidal activity and is an important defense 
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mechanism for the body. However, it also can cause damage to the tissues and it has 
been implicated in the development of autoimmune disorders. 
While inflammation was typically considered a downstream event to the 
amyloid hypothesis, Aβ causes microglia activation, neuroinflammation may worsen 
the course of disease. When fully activated, microglial cells produce pro-
inflammatory cytokines including TNF-α, interleukin-6 (1L-6), and interleukin-1β 
(IL-1β) [182]. These pro-inflammatory cytokines and activated complement factors 
has led to the idea that neuroinflammation is involved in the pathology of Alzheimer’s 
disease. Indeed, the activated microglial cells were increased in AD progression, 
suggesting that Aβ deposition stimulates microglial activation. Several studies have 
shown that microglia can surrounds Aβ plaques and can phagocytose Aβ [183-185]. 
Microglia can be stimulated by a variety of substances to yield an inflammatory 
phenotype in the brain. Induction of a proinflammatory phenotype by LPS or TNF-α 
cause Aβ clearance [186, 187]. On the other hand, anti-inflammatory cytokines 
induction exacerbated Aβ deposition [188]. In a 2015 publication, a long-term 
induction of anti-inflammatory cytokine IL-10 showed a significant increase in Aβ 
deposition and led to cognitive behavior in APP transgenic mice model [189]. Thus, 
we postulate high levels of these markers can represent progression of AD. Several 
clinical anti-inflammatory drugs targeting COX or TNF-α have been investigated for 
their effects on AD via population-based studies or randomized controlled clinical 
trials, yet have yielded no clinical AD therapies so far [190]. On the other hand, several 
compounds that suppress neuroinflammatory responses have been identified from 
screening campaigns but not yet translated into effective AD drugs [191, 192]. 
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1.9 Treatment of Alzheimer’s Disease 
To date, the Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA) have approved only medications for alleviating symptoms for AD 
patients.  
These medications include acetylcholinesterase (AChE) inhibitors such as donepezil, 
galantamine, rivastigmine, and a NMDA receptor antagonist, memantine. AChE 
inhibitors are used to induce the level of acetylcholine at synapses restraining the loss 
of neurotransmission found in AD. On the other hand, a NMDA receptor antagonist 
regulates glutamate-induced toxicity. 
Donepezil hydrochloride (brand name Aricept) approved in 1996 for 
treatment of all stages of AD by preventing the breakdown of acetylcholine in the 
brain is a highly selective and reversible antagonist for AChE. In a 1998 publication, 
Rogers et al. reported the effect of donepezil hydrochloride on 468 participants who 
had mild to moderate AD. In this study, 32% of the 5mg treatment group and 38% of 
the 10 mg treatment group showed clinical improvement on various psychiatric 
scales, indicating donepezil is effective in cognition and global function decline in AD 
[193]. So far, donepezil is the only AchE inhibitor approved for treatment of severe 
AD.  
Rivastigmine tartrate (brand name Exelon) approved in 2000 is less 
frequently used than other AChE inhibitors for treatment of mild to moderate AD 
patients. Lanctot et al reported the effect of rivastigmine at different dosages and 
various treatment intervals. The patients administered at high dose (6-12mg/day) 
showed dramatic improvement in cognitive function at all intervals (12, 18, and 26 
weeks), proving treatment of rivastigmine at 6-12mg daily over a long time periods 
may be an effective strategy [194].  
Galantamine hydrobromide (brand name Razadyne) approved in 2001 for 
treatment of mild to moderate AD by inhibiting the hydrolysis and increasing the 
concentration of acetylcholine. Galantamine is a specific, competitive, and reversible 
AChE inhibitor. As described in a 2006 review article by Loy and Schneider et al., 
36 
 
treatment of galantamine (18-32 mg/day) showed significant improvement on 
cognitive symptoms at 3 months and 6 months intervals [195]. 
Memantine (brand name Namenda) was approved by FDA in 2003 for 
treatment of moderate to severe AD [196]. Memantine is a noncompetitive NMDA 
receptor antagonist, blocking glutamatergic receptors and regulates the action of 
glutamate. Under physiological conditions, magnesium ions are capable of blocking 
NMDA receptor which is a glutamate receptor and ion channel protein found in nerve 
cells. Glutamate signaling enhances depolarization of the post-synaptic membrane 
and unblock NMDA allowing calcium ions to flow into the postsynaptic neuron. In AD, 
however, constantly stimulated glutamate and over-activated NMDA receptor could 
be observed, causing cognitive impairment. Thus, memantine is considered as a 
neuroprotective agent by preventing excess glutamate-related excitotoxicity [197]. In 
a 2003 publication, Reisberg et al. showed memantine regulated NMDA receptors, 
leading to alleviation of AD symptoms. Among 345 elderly participants with 
moderate to severe AD, 29% of the memantine treated group showed the 
improvement of cognitive dysfunctions [198]. Although memantine has shown to 
positive results to reduce the rate of cognitive decline, it is not also capable of 
preventing the neuronal damage detected in AD.  
1.10 Efforts to Develop Alzheimer’s Disease Therapeutics 
As we discussed previously, evidence supporting the amyloid theory led to 
development of AD therapeutics either disrupting aggregation, or promoting removal 
of Aβ. Based on the amyloid theory, Inhibitors targeting Aβ aggregation have been 
developed, including glycosaminoglycan 3-amino-1-propaneosulfonic acid (3APS), 
colostrinin, scyllo-inositol and Zinc/Copper chelators. Among these compounds, only 
3APS designed to interfere with endogenous glycosaminoglycans, which were shown 
to promote aggregation of Aβ, has reached to phase III clinical trials, however, results 
of the clinical trials were disappointing [199]. 
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Immunotherapy has been one of the most attractive approaches for AD drug 
development. It has been reported that both vaccination and monoclonal antibodies 
approaches have been developed to be successful. At the first time, using an active 
vaccine (AN1792) with Aβ1-42 showed the promising results only in preclinical studies, 
but not in clinical trials with side effect such as encephalitis [200]. Since encephalitis 
was found in one patient treated with AN1792 in a Phase I clinical trial who died 
approximately one year after her last injection, vaccines have been developed to 
improve the safety issue. However, the various types of antibody responses were 
found in elderly and it led to further investigation of passive immunization using 
monoclonal antibodies.  
Bapineuzumab (Janssen/Pfizer) and Solanezumab (Eli Lilly) are monoclonal 
antibodies designed to increase the clearance of Aβ and have been heavily 
investigated. Bapineuzumab is a humanized, N-terminal specific anti-Aβ monoclonal 
antibody, binding to neurotoxic amyloid proteins in the brain. Several preclinical 
studies have shown that passive immunotherapy with monoclonal antibodies led to 
a significant clearance of Aβ protein levels in the brain and improved the memory loss 
in transgenic mouse models with excessive Aβ proteins [201-205]. Additionally, 
phase II clinical trials have shown that bapineuzumab can reduce deposition of 
amyloid proteins and the concentration of phosphorylated tau proteins in the 
cerebrospinal fluid [206, 207]. Based on ongoing Phase II study, Elan/Wyeth 
announced the start of the Phase III clinical trials for bapineuzumab on May 2007. 
However, bapineuzumab was failed in phase III clinical trials [208]. Solanezumab 
developed by Lilly, on the other hand, is a monoclonal antibody that recognizes an 
epitope in the core of the amyloid peptide, binding to soluble Aβ and with low affinity 
for the fibrillar Aβ form. Solanezumab has also been tested in two phase III clinical 
trials (Expedition 1 and 2) in a population of patients with mild to moderate AD 
similar to that in trials with bapineuzumab. Unfortunately, it was recently found that 
solanezumab also could not meet its clinical endpoints for efficacy in patients with 
mild AD [209]. The human monoclonal antibody Aducanumab (Biogen) is another 
attractive passive immunization strategy for treatment of AD and has been fast-
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tracked to phase III clinical trials. Aducanumab is currently being evaluated in two 
global Phase 3 studies (ENGAGE and EMERGE) designed to evaluate its safety and 
efficacy in slowing cognitive impairment in people with very early AD or mild AD. This 
study is set to end in April 2022. 
 Considerable efforts to prevent Aβ production have focused on inhibiting β- 
secretase, which are responsible for production of Αβ since the proteolytic processing 
of APP by β-secretase (beta-site APP cleaving enzyme 1, BACE1) is the rate-limiting 
step in the production of Aβ. Thus, BACE1 is thought to be a major therapeutic target 
and BACE1 inhibitors have the potential to be disease-modifying drugs for AD 
treatment. Due to the location of BACE1 in the brain BACE1 inhibitors need to cross 
the BBB to access the target and it is quite challenging [210]. Furthermore, BACE1 
displays the large catalytic pocket, suggesting BACE1 inhibitor needs to be large 
enough to interact with the active site though the inhibitors also should be small 
enough to have drug-like physiochemical properties [211]. Vassar also reported that 
several BACE1 inhibitors during the clinical trials showed off-target toxicity, 
indicating the inhibitors are also required to be selective over other aspartic 
proteases to prevent toxic effects by cross inhibition. With efforts to search for 
effective and selective BACE1 inhibitors, some compounds have shown promising 
results in preclinical studies and six drugs, JNJ-54861911, CNP520, LY3202626, 
elenbecestat, lanabecestat, and verubecestat, are currently being evaluated in clinical 
trials in patients with mild to moderate AD [212, 213]. Especially, verubecestat was 
the first BACE1 inhibitor to reach to phase III clinical trials. However, Merck has 
discontinued its pivotal trial in patients with mild to moderate AD due to low efficacy 
in cognitive decline reduction [214]. Consequently, these disappointing results 
remain questions regarding the potential use of BACE1 inhibitors as AD drugs. 
Nevertheless, recent results from an animal model to mimic BACE1 inhibition in 
patients with AD by deletion of BACE1 support that BACE1 inhibition can completely 
reduce amyloid pathology and inhibiting BACE1 may have a potential for treatment 
of AD [215].  
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The large body of results showing tau protein aggregates accumulated in the 
brain of AD patients highly led to investigation of therapeutic strategy targeting tau 
to treat AD patients. Preclinical studies from the transgenic mouse models using 
various anti-tau antibodies have shown that antibodies against tau prevented 
extracellular trans-synaptic transmission of misfolded tau between cells. Following 
toxicology studies, the compound C2N-8E12, now known as ABBV-8E12 (AbbVie & 
C2N Diagnostics), was reached to initiation of clinical trials in 2015. In a phase I 
clinical study safety, tolerability and pharmacokinetics of ABBV-BE12 were tested on 
32 patients. As a result, ABBV-BE12 was found to be safe and tolerable when single 
injected into the blood [216-218]. Positive results from a phase I trial led to phase II 
clinical trials of ABBV-BE12 and the study is set to end in May 2019. Another anti-tau 
monoclonal antibody BIIB029 (Biogen) was also moved to phase II clinical trials with 
the patients with early AD and the estimated study completion date is July 2021 [219, 
220]. 
Azeliragon (vTv Therapeutics Inc), also known as TTP488, is an orally 
bioavailable small molecule that inhibits the receptor for advanced glycation end 
products (RAGE) that is thought to be involved in the development of Alzheimer’s 
disease. RAGE found in the brain and the periphery is an immunoglobulin family 
member and is expressed in endothelial cells and microglia cells and is upregulated 
in AD [221-224]. In a 2012 publication, Li et al. suggested that RAGE may contribute 
to AD pathology by promoting influx of peripheral Aβ into brain and regulating Aβ 
induced oxidative stress, mediating AGE induced hyperphosphorylation of tau [225]. 
RAGE is also thought to interfere with inflammation and transfer Aβ into the brain. A 
number of preclinical studies and positive results of phase I/II clinical trials led to 
phase III clinical trials of azeliragon to evaluate the efficacy and safety of this 
compound in patients with mild Alzheimer's disease. The company vTv Therapeutics, 
conducting a phase III trials of the drug in mild AD, announced preliminary results in 
early 2018. Unfortunately, the study was terminated due to a lack of efficacy at the 5 
mg azeliragon dose [226].  
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Lumateperone (Intra-Cellular Therapies Inc), known as ITI-007, is a first-in-
class molecule designed to selectively and simultaneously modulate certain neuronal 
pathways. This molecule acts on serotonin, dopamine, and glutamate receptors. It is 
an investigational therapy being developed to treat agitation in dementia, including 
Alzheimer's disease and mental illness as well as schizophrenia. In 2014, Intra-
Cellular announced the phase I/II clinical trials results that lumateperone was safe 
and well-tolerated and showed improved cognitive function and thereby the phase 
III clinical trials were initiated in 2016 to evaluate the efficacy and safety of 
lumateperone in about 360 people diagnosed with probable Alzheimer’s disease 
[227,228]. Lumateperone, however, was not likely to meet its primary endpoint upon 
completion and therefore the study was stopped for futility in Dec 2018 [229]. 
 
1.11 Proteasome in Alzheimer’s Disease 
While years of debate have not provided a conclusive answer to the question of 
events related to the proteasome causing to AD pathology, there is growing evidence 
showing changes in the UPS have been associated with AD [230-232]. In the early 
phase of AD, proteasome activity was decreased, and ubiquitin accumulation found 
in plaques and tangles was also associated in late AD [231, 233-236]. Interestingly, it 
was reported alterations in the UPS affect the degradation of Aβ in neurons and 
astrocytes. In addition, Aβ oligomers downregulated in vitro proteasome activity and 
lower proteasome activity was also observed in the several brain areas of AD patients 
[237-239]. However, these studies were limited to assess the proteasome activity in 
whole brain homogenates or in cell line models, not examining activity and the 
expression levels of immunoproteasome in glial cells. While the role of 
immunoproteasome in neuroinflammation is not clearly understood, researchers 
also observed whether expression and activity of immunoproteasome are involved in 
microglial activation in AD patients and in a mouse model of brain injury [240-243]. 
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In a 2006 publication, Mishto reported that β1i expression was elevated with age, and 
in the brain of AD patients [244]. In line with this, Orre et al. showed that activities of 
immunoproteasome subunits were increased along with promoted plaque in AD mice 
and patients, suggesting the tight correlation between upregulation of 
immunoproteasome and reactive astrocytes and microglial cells derived from 
patients with AD [240]. Importantly, most recent study has shown that LMP7/β5i 
knockout altered microglial cytokine production profiles and improved cognitive 
dysfunctions in a mouse model of Aβ deposition, indicating a potential role of 
immunoproteasome in Aβ-induced neuroinflammation [51]. While it becomes clear 
that immunoproteasome activity is enhanced in microglia of AD, suggesting the 
involvement of immunoproteasome in neuroinflammatory responses and 
therapeutic potential for AD treatment, it is still unknown whether 
immunoproteasome selective inhibitors display pharmacological inhibition on AD 
pathology.  
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CHAPTER 2. HYPOTHESIS AND SPECIFIC AIMS 
 
The overall goal of this research is to develop novel, effective proteasome 
inhibitors for treating multiple myeloma patients who do not respond to PI therapies 
and Alzheimer’s disease patients.  
In order to design new and effective therapeutic strategies to bypass resistance, 
it is important to better understand the mechanisms of proteasome inhibitors 
resistance. Recently, several studies have shown that UPS-targeting inhibitors retain 
anticancer activity in Btz-resistant MM cells, indicating that the UPS remains essential 
in these cells [245, 246]. Furthermore, PIs other than Btz remained cytotoxic to Btz-
resistant MM cells [247], suggesting that alternative PIs can overcome Btz resistance. 
However, information on the ability of UPS-targeting inhibitors to overcome Cfz 
resistance is currently limited. Additionally, it is currently unclear whether the 
proteasome is still a valid target in Cfz-resistant cancer cells. To date, investigations 
of Cfz resistance have largely focused on acquired resistance due to the Cfz-adapted 
cancer cell line models and the availability of clinical samples derived from patients 
who have developed resistance after prolonged Cfz therapy. On the other hand, 
mechanistic investigations of de novo Cfz resistance have been scarce, due to the lack 
of appropriate cell line models and patient samples. We hypothesized that 
proteasome function remains vital to the survival of de novo Cfz-resistant cancer cells, 
and that targeting the proteasome using alternative proteasome inhibitors is a good 
strategy to overcome Cfz resistance.  
As described previously, the immunoproteasome known to be involved in 
regulation of inflammatory immune responses, is currently investigated as a potential 
therapeutic target for autoimmune diseases [51, 248]. Likewise, the 
immunoproteasome is also reported to be upregulated in in reactive astrocytes and 
microglia isolated from AD patients and AD mouse models [240, 241, 244, 249, 250]. 
However, the physiological role of immunoproteasome in these AD brains, is still 
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completely unknown. Recent study showed LMP7 knockout altered microglial 
cytokine production profiles and improved cognitive deficits in a mouse model of Aβ 
deposition, indicating a potential role of immunoproteasome in Aβ-induced 
neuroinflammation [51]. Interestingly, moderate up-regulation of LMP2 expression 
in AD patients was also reported. Despite these data suggesting the involvement of 
immunoproteasome in neuroinflammatory responses and therapeutic potential for 
AD treatment, the pharmacological inhibition of LMP2 has never been tested for the 
impact on AD pathology. With this in mind, we also hypothesize whether LMP2 
inhibitors could offer a novel strategy in AD progression via regulation of 
inflammation.  Our overall study had the following aims: 
Aim 1. Determine whether alterations in proteasome catalytic subunit 
composition are causally linked with changes in the sensitivity of cancer cells 
to Cfz. I initially identified the first de novo Cfz-resistant cancer cell line model. 
Proteasome activity and immunoblotting analyses were used to detect changes in 
proteasome catalytic subunits. I altered proteasome catalytic subunit compositions 
in cancer cell lines using genetic (overexpression & knockdown) and biochemical 
(INF-γ) tools and investigated whether those alterations led to changes in 
proteasome inhibitor sensitivity in Cfz-resistant cancer cells. 
Aim 2.  Optimize small molecules that inhibit the growth of Cfz-resistant 
cancer cells. I performed cell-based screens of in-house proteasome inhibitor 
libraries containing proteasome catalytic subunit-specific inhibitors to identify 
compounds that are effective against Cfz-resistant cancer cells. Using selected lead 
compounds, I tested their efficacy against primary multiple myeloma cells derived 
from patients who are proteasome inhibitor-resistant. To improve the potency of the 
lead compound, we utilized a previously reported docking model of the compound to 
its targets. Traditional medicinal chemistry was performed to design and synthesize 
analogues of the most promising hit compound. Compound analogues were assayed 
for in vitro proteasome inhibitory activity and later for their cytotoxic activity in Cfz-
resistant cancer cells. 
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Aim 3. Investigate whether LMP2 inhibitor has anti-AD activity via 
regulation of inflammation: We assessed animal behavior tests using LPS-induced 
inflammatory and transgenic AD mouse models to examine the effects of proteasome 
inhibitors on cognitive impairments.  ELISA assay, Thioflavin staining of amyloid-beta, 
and HEK293-tau-BiFC cells were utilized to investigate the effect of the proteasome 
inhibitors on amyloid-beta or tau aggregation, respectively. Membrane cytokine 
array and ELISA assay were used to evaluate the effect of the compound on pro-
inflammatory cytokines in microglial cells.  
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CHAPTER 3. H727 CELLS ARE INTRINSICALLY RESISTANT TO THE 
PROTEASOME INHIBITOR CARFILZOMIB, YET REMAIN DEPENDENT ON THE 
PROTEASOME FOR CELL SURVIVAL AND GROWTH  
The work in this chapter was published in Scientific Reports 2019, 9, 4089 [333].  
3.1 Introduction 
The proteasome controls numerous cellular processes via the regulated 
degradation of proteins. Despite its essential functions, it is now understood that 
agents which inhibit the proteasome have therapeutic selectivity for cancer cells as 
compared to normal cells. This selectivity likely occurs because rapidly proliferating 
cells have greater protein degradation requirements and due to the proteasome’s role 
in regulating a variety of critical signaling pathways. In general, 20S proteasomes 
were thought to exist in two main types, the constitutive proteasome (cP) and the 
immunoproteasome (iP). More recently, various subtypes of proteasomes containing 
a non-standard mixture of catalytic subunits have been identified in cancer cell lines. 
These so-called intermediate proteasomes differ from both constitutive and 
immunoproteasomes, which contain mixed assortments of cP and iP catalytic 
subunits, such as β1i-β2-β5i [251-255]. It was further reported that these 
intermediate proteasomes may confer differing sensitivities to proteasome inhibitors 
(PIs) as compared to cPs or iPs [253, 254, 256]. However, whether intermediate 
proteasome subtypes contribute to the resistance of cancer cells to proteasome 
inhibitors is currently unknown and the clinical implications of intermediate 
proteasomes have yet to be defined.  
The clinical and commercial successes of bortezomib (Btz, Velcade®), 
carfilzomib (Cfz, Kyprolis®), and ixazomib (Ixz, Ninlaro®) have validated the 
proteasome as a valuable target in the treatment of cancer. While the first-in-class 
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proteasome inhibitor (PI) drug Btz and the first oral PI Ixz utilize boronic acid 
pharmacophores, the second-generation PI Cfz harbors an epoxyketone that 
irreversibly inactivates the proteasome with high mechanistic selectivity [257, 258]. 
This selectivity affords Cfz a reduction in off-target interactions yielding an improved 
safety profile over Btz, most notably a reduced incidence of severe peripheral 
neuropathy[259]. With positive results from recent phase III clinical trials [260-265], 
Cfz is now firmly placed as a mainstay of refractory MM therapy. Nevertheless, a 
considerable portion of MM patients are refractory to Cfz or develop resistance after 
prolonged Cfz treatment. A meta-analysis of 14 clinical trials found that 44% of 
patients could not achieve a minimal response or better [266]. As a monotherapy in 
patients with relapsed MM, for example, the response rates for Cfz were in the ranges 
of 25-40% [267]. When used in combination with other drugs (often with 
dexamethasone and/or lenalidomide), response rates substantially improved, but a 
significant subset of non-responders persisted [105,106, 265, 268, 269]. Even for 
those who initially respond to Cfz-based therapy, disease eventually relapses with a 
median progression-free-survival (PFS) of ~17-26 months [105, 106]. To date, 
extensive efforts have been yielding the development of new therapeutics for these 
Cfz resistant patients. However, clinical effects of the new therapeutics are 
disappointing likely due to a lack of understanding of the biological mechanisms 
underlying Cfz resistance.  
Mechanistic investigations of Cfz resistance have so far utilized cancer cell lines 
adapted to gradually increasing concentrations of Cfz, revealing that the 
overexpression of P-glycoprotein (P-gp) and mutations or 
amplification/overexpression of proteasome catalytic subunits are largely 
responsible for acquired Cfz resistance observed in established cell lines [132, 133]. 
To date, cell-based models of de novo Cfz resistance are unavailable. Here, we report 
for the first time that H727 cells (derived from a human bronchial carcinoid tumor) 
are inherently resistant to Cfz, yet remain dependent on the proteasome for their 
survival and growth. Our current results suggest that de novo Cfz resistance observed 
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in H727 cells may be mediated at the 20S proteasome level, providing previously 
unknown insights into the mechanisms of de novo PI resistance.      
 
3.2 Material and Methods 
3.2.1  Cell lines and chemicals 
Hep3B, Huh7, LCSC, HepG2, and PLC/PRF/5 hepatic cancer cells were a kind gift of 
Dr. Roberto Gedaly (College of Medicine, University of Kentucky). MDA-MB-231, 
HCC1143, and HCC1937 breast cancer cells were purchased from the Korean Cell Line 
Bank (Seoul, Korea).  All other established cell lines were obtained from the American 
Type Culture Collection (ATCC, Rockville, MD). All cells were cultured according to 
the manufacturer’s protocol in 5% CO2 in medium. Cultured cell lines were tested for 
Mycoplasma contamination routinely every 6 months. Specifically, H23 and H727 
cells were tested three times in the course of performing the experiments described 
within this dissertation work. Inhibitors of UPS pathways used in this study were 
purchased from commercial vendors: carfilzomib (LC Laboratories, Woburn, MA), 
bortezomib (ChemieTek, Indianapolis, IN), MG-132 (EMD Millipore, San Diego, CA), 
PYR-41 (ApexBio, Houston, TX), and P5091 (ApexBio, Houston, TX). The following 
proteasome fluorogenic substrates were used: Suc-LLVY-AMC (Bachem, Torrance, CA; 
I-1395), Ac-WLA-AMC (Boston Biochem, Cambridge, MA; S-330), Ac-nLPnLD-AMC 
(Bachem; I-1850), Ac-RLR-AMC (Boston Biochem; S-290), Ac-ANW-AMC (Boston 
Biochem; S-320), and Ac-PAL-AMC (Boston Biochem; S-310). Human recombinant 
Interferon-γ was purchased from eBioscience (San Diego, CA). 
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3.2.2 Cell viability assay 
Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation 
assay (Promega, Madison, WI) according to the manufacturer’s protocol. Briefly, cells 
were seeded at a density of 5,000-10,000 per well in 96-well plates and allowed 24 
hours to attach. After cells were treated with the indicated concentrations of 
compounds for 72 hours, cell viability was measured using the reagent provided in 
the assay kit. Absorbance at 490 nm was measured using a SpectraMax M5 microplate 
reader (Molecular Devices, Sunnyvale, CA). Results were analyzed using GraphPad 
Prism (La Jolla, CA). 
 
3.2.3 Immunoblotting 
Total cell lysates containing equivalent protein content were separated by 12% SDS-
PAGE and transferred to polyvinylidene difluoride membranes (Millipore, Billerica, 
MA) via a semi-dry apparatus. Membranes were then blocked in 5% non-fat dry milk 
(Bio-Rad, Hercules, CA) in Tris-buffered saline with 0.05% Tween-20 (TBST) for 1 h 
at room temperature, followed by incubation with 3% BSA in TBST containing the 
respective primary antibodies overnight at 4°C: β1 (Enzo Life Sciences; PW8140), β2 
(Enzo Life Sciences; PW8145), β5 (Thermo Scientific; PA1-977), β1i (Abcam; ab3328), 
β5i (Abcam; ab3329), β-actin (Novus Biologicals; NB600-501), and β2i (Santa Cruz; 
sc-133236; 3% milk-TBST used for dilution). Membranes were then washed five 
times with TBST and incubated with HRP (Horse radish peroxidase)-conjugated 
secondary antibodies for 1 hour at room temperature. Immunoreactive bands were 
visualized using SuperSignal West Femto Chemiluminescent Substrate (Thermo 
Scientific, Rockford, IL) and X-ray film (Thermo Scientific or GeneMate). 
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3.2.4 Proteasome Activity Assay 
Subunit-selective fluorogenic peptide substrates were used to measure the catalytic 
activities of individual catalytic subunits by monitoring the rate of substrate 
hydrolysis over time. Briefly, protein lysates were prepared using passive lysis buffer 
(Promega, Madison, WI) and diluted in 20S proteasome assay buffer (20 mM Tris-HCl, 
0.5 mM EDTA, 0.035% SDS, pH 8.0). Enzyme reactions were initiated by the addition 
of proteasome substrates. Substrates and concentrations were used as following: Suc-
LLVY-AMC (β5/5i, 100 µM), Ac-WLA-AMC (β5, 20 µM), Ac-nLPnLD-AMC (β1,100 µM), 
Ac-RLR-AMC (β2/2i, 20 µM), Ac-ANW-AMC (β5i, 100 µM), and Ac-PAL-AMC (β1i 
activity, 100 µM). Fluorescence signals were measured over 1 hour at one reading per 
one minute using a SpectraMax M5 microplate reader at the excitation and emission 
wavelengths of 360 and 460 nm, respectively. 
 
3.2.5 Interferon-γ treatment 
H727 and H23 cells were treated with 150 U⋅ml-1 of IFN-γ or vehicle for 24 h. At the 
end of IFN-γ treatment, the cells were washed with PBS three times and then cultured 
for an additional 24 hours. Afterwards the cells were sub-cultured into a 96-well plate, 
and cell viability assays was performed using CellTiter 96 AQueous One Solution Cell 
Proliferation assay (Promega, Madison, WI) as described above. The remaining cells 
were then used for immunoblotting analysis and proteasome activity assays. 
 
3.2.6 Knockdown of proteasome catalytic subunits 
Cells were transfected with ON-TARGET Plus Smart Pool siRNAs (Dharmacon, 
Lafayette, CO) using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, 
CA), according to the manufacturer’s instructions. H727 cells were plated in a 6-well 
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plate at a density of 5x105 cells per well and allowed at least 24 h to attach. Cells were 
then transfected with 100 nmole of siRNAs and Lipofectamine 2000. At 4 h post-
transfection, serum-free Opti-MEM medium (Invitrogen, Carlsbad, CA) was replaced 
with complete medium and the cells were incubated for 48 h. The following siRNA 
pools were used: PSMB5 (L-004522-00-0020), PSMB7 (L-006021-00-0020), PSMB8 
(L-006022-00-0020), PSMB9 (L-006023-00-0005), and PSMB10 (L-006019-00-
0020). For the negative control, human non-targeting scrambled siRNA (D-001810-
10) was used. 
 
3.2.7 Preparation of primary MM samples 
 Cryopreserved MM primary cells isolated from the bone marrow or peripheral blood 
of patients with no reported history of PI treatment were purchased from Conversant 
Biologics (Huntsville, AL) and AllCells (Alameda, CA). CD138-positive cells were 
isolated from patient samples immediately after thawing using human CD138 
microbeads (Miltenyi Biotec), whole blood column kit (Miltenyi Biotec), MidiMACS 
magnetic separator (Miltenyi Biotec), and 30 µm MACS SmartStrainers (Miltenyi 
Biotec). Purified cells were plated on white 96-well cell culture plates at 40,000 cells 
per well in RPMI 1640 media supplemented with 10% FBS. Cells were treated with 
proteasome inhibitors for 48 hours before viability assessment via CellTiter-Glo 
Luminescent Cell Viability Assay (Bio-Rad).  
 
3.2.8 Statistics analysis 
Results are expressed as means ± S.D. Statistical significance of the observed 
differences was determined using Student’s t-test (with the Holm-Sidak method when 
appropriate).  All statistical analyses were carried out using GraphPad Prism 7.04 
(GraphPad Software). 
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3.3 Results 
3.3.1 H727 cells are intrinsically resistant to Cfz 
To identify Cfz-resistant cell lines, we first measured the cytotoxic effects of 
Cfz in 21 cancer cell lines derived from various types of cancer. These cell lines 
displayed an array of Cfz sensitivities (IC50 values ranged from 9 to 610.2 nM). We 
were especially intrigued by the marked lack of response to Cfz in the H727 human 
non-small cell lung cancer (NSCLC) cell line; the Cfz I IC50 value for this cell line (610.2 
nM) was approximately 33-fold higher than that for the Cfz-sensitive NSCLC cell line 
H23 (18.3 nM) (Figure 3.1A). Even in the presence of 250 nM of Cfz which usually 
induces >95% loss of viability in most of other cancer cell lines including H23 cells, 
H727 cells survived and grew normally (Figure 3.1B). Thus, we selected the H727 cell 
line as our cell line model of intrinsic resistance to Cfz in which to test our hypothesis.  
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Figure 3.1 Sensitivity of H23 and H727 cells to Cfz  
A.  Cell viability (IC50 values) for a panel of established cancer cell lines as measured 
by MTS assay following incubation with carfilzomib (Cfz) for 72 h. H727 cells are most 
resistant to Cfz among 21 tested cell lines. B. Representative images of H23 and H727 
cells growing in the presence of Cfz (100 or 250 nM, respectively) assessed via light 
microscopy for 3 days. 
Day 2 Day 3 
H23 
Carfilfomib 
(100nM) 
H727 
Carfilzomib 
(250 nM) 
Day 0 
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3.3.2 Previously reported mechanisms do not explain de novo resistance of H727 cells  
While the mechanisms of intrinsic resistance to Cfz has not been reported to 
date, several studies have shown that P-gp can contribute to acquired resistance to 
Cfz observed in cancer cell line models and clinical samples from patients with prior 
Cfz therapy [132-135]. To test whether P-gp plays a role in the de novo Cfz resistance 
of H727 cells, we performed immunoblotting analysis but found no detectable P-gp 
expression (Figure 3.2A). Furthermore, treatment of H727 cells with reversin 121, a 
dipeptide P-gp inhibitor, did not significantly impact the IC50 value of Cfz (Figure 
3.2B), confirming a P-gp-independent mechanism of resistance. Next, we examined 
the possibility that Cfz may undergo rapid metabolic inactivation in H727 cells. We 
treated H727 and H23 (Cfz-sensitive) cells with 500 nM Cfz and collected culture 
media to measure the levels of remaining Cfz at 6 or 24 h post-treatment. The level of 
remaining drug was overall comparable between H727 and H23 cells although a 
slight difference was noted at 24 h (Figure 3.2C). Direct sequencing analyses also 
indicated that the PSMB5 (encoding β5) and PSMB8 (encoding β5i) genes in H727 
cells harbor no mutations (Figure 3.3A-D). We attempted to compare the intracellular 
drug levels by quantifying the remaining drug levels in lysates of H727 and H23 cells, 
but the levels were below the lower limit of quantitation (< 5 nM) of our current 
analytical assay. Although it was not feasible to assess the intracellular drug levels, 
H727 cells contained Cfz in the culture media at the level comparable to or slightly 
higher than H23 cells. Assuming that Cfz primarily enters cells via passive diffusion 
(no report yet supporting the presence of uptake transporters for Cfz as far as we 
know), it appears unlikely that H727 cells have intracellular Cfz levels much lower 
than H23 cells. Taken together, de novo resistance of H727 cells was not explained by 
previously reported mechanisms such as P-gp upregulation, genetic mutations in 
proteasome catalytic subunits, or enhanced metabolic inactivation of Cfz.   
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Figure 3.2 Independency of H727 cells in previously reported mechanisms  
A.  Immunoblotting results showing no detectable expression of P-glycoprotein (P-gp) 
in H727 cells. DLD-1 cells with acquired Cfz resistance via P-gp upregulation (DLD-
1/CfzR) were used as a positive control. B. The co-treatment of reversin-121 (7.5 µM, 
P-gp inhibitor) did not affect the sensitivity of H727 cells to Cfz. The IC50 values did 
not show statistically significant difference between in the presence and absence of 
reversin-121 (Student’s t-test). C. The levels of remaining Cfz in culture media were 
comparable between H727 and H23 cells (no statistically significant differences, t-
tests the Holm-Sidak method to correct for multiple comparisons with α = 0.05) (This 
experiment was performed by Ji Eun Park from Wooin Lee’s group in the College of 
Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National 
University, Korea)   
55 
 
A 
 
 
Figure 3.3† Sequencing analysis of the PSMB5 and PSMB8 genes in H727 cells 
A.  Alignment of truncated H727 PSMB5 forward sequencing read to PSMB5 
NM_002797.4. B. Alignment of truncated H727 PSMB5 reverse sequencing read to 
PSMB5 NM_002797.4.  C. Alignment of H727 PSMB8E2 forward sequencing read to 
truncated PSMB8E2 NM_148919.3 ORF. D. Alignment of H727 PSMB8E2 reverse 
sequencing read reverse-compliment to truncated PSMB8E2 NM_148919.3 ORF.  
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Figure 3.3† (continued) 
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Figure 3.3† (continued) 
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Figure 3.3† (continued) 
 
 
 
 
 
† Sequencing analysis data of the PSMB5 and PSMB8 genes in H727 cells were 
acquired by Zachary Miller.  
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3.3.3 The proteasome remains essential for the survival of H727 cells 
It is possible that cancer cells might have adaptations to endure reduced levels 
of 20S proteasome function and the rely on the non-proteasomal protein degradation 
pathways to reduce proteasome load. In order to verify whether the UPS is important 
for the survival and proliferation of Cfz-resistant H727 cells, as it is in Cfz-sensitive 
cell lines such as H23, we first transfected cells with siRNAs targeting the proteasome 
α7 subunit in H727 cells, thereby blocking the assembly of active 20S proteasomes. 
[270, 271]. As seen in Figure 3.4A, effective silencing of α7 resulted in almost complete 
cell death after 3 days post-transfection for both in H727 and H23 cells, indicating 
that active proteasomes remain indispensable for the survival of Cfz-resistant H727 
cells. These results suggested that H727 cells may still respond to proteasome 
inhibitors other than Cfz. In order to examine this, we treated H727 cells with 
alternative PIs, particularly ones with differing pharmacophores or structures, such 
as Btz (a peptide boronic acid) and MG-132 (a peptide aldehyde). These PIs were 
indeed highly effective in killing H727 cells and their IC50 values were comparable 
between H727 and H23 cells (Figure 3.4B). We also used two inhibitors targeting 
various upstream components of the UPS, PYR-41, an inhibitor of ubiquitin E1 ligase 
and several DUBs, and P5091, a specific USP7/USP47 inhibitor [245]. Both PYR-41 
and P5091 were cytotoxic in H727 and H23 cells with comparable potencies (Figure 
3.4B). These results further support that H727 cells remain dependent on the 
ubiquitin-proteasome system, despite their de novo resistance to Cfz. 
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Figure 3.4 Cytotoxic effect of targeting the UPS in H727 cells  
A.  Knockdown of proteasome α7 subunit in H727 cells effectively induced cell death 
to a similar extent as observed in H23 cells (images taken 48 h post-transfection). 
Immunoblotting analysis was performed to verify the efficient knockdown of α7 in 
H727 cells. B. Comparison of the sensitivity (IC50 values) of H727 and H23 cells to 
carfilzomib, bortezomib, MG 132, PYR-41 (an E1 inhibitor) and P5091 (an 
USP7/USP47 inhibitor). Data are shown as mean ± SD derived from a non-linear 
regression based on n=3-4 replicates per compound per concentration. 
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3.3.4  H727 cells have a distinct composition of proteasome catalytic subunits 
To account for the sensitivity of H727 cells to other PIs, we hypothesized 
whether the subunit composition at the 20S proteasome level may contribute to de 
novo resistance of H727 cells to Cfz. To test this hypothesis, we compared the 
proteasome catalytic subunit expression and activity profiles of H727 and H23 cells 
via immunoblotting analysis and kinetics assays using fluorogenic substrates for 
individual subunits (β1, β5, β1i, β5i). In the case of the β2 and β2i subunits, their 
combined trypsin-like activity was assessed due to the lack of a specific fluorogenic 
substrate that can distinguish the two subunits. As shown in Figure 3.5A., the 
expression pattern of proteasome catalytic subunits in H727 cells differed from that 
in Cfz-sensitive H23, panc-1, and RPMI 8226 cells. H727 cells expressed high levels of 
β1, β2, and β5i, while β1i expression was undetectable. The expression profile of 
catalytic subunits in H727 cells was not consistent with those typically expected for 
the two main 20S proteasome subtypes, namely a set of β1-β2-β5 for cP or an 
immuno-subunit set of β1i-β2i-β5i for iP. Substantial differences were also noted 
when the activity profiles of proteasome catalytic subunits were compared between 
these two cell lines using subunit-selective fluorogenic substrates (Figure 3.5B). 
Interestingly, the activity profiles of individual catalytic subunits showed 
discrepancies with the protein levels of the respective catalytic subunits. We suspect 
that the observed differences may reflect the complex relationship between 
proteasome structure and function (e.g. contributions of post-translational 
modifications, regulatory particles, or non-standard composition of proteasome 
catalytic subunits to the hydrolysis rates of fluorogenic substrates).  
We next examined whether individual subunits of proteasomes in H727 cells 
may display different proteasome inhibition profiles than those of H23 cells. We 
treated H727 and H23 cells with 20 nM of Cfz for 4 h and measured the remaining 
activities of individual catalytic subunits relative to vehicle-treated control cells. As 
shown in Figure 3.5C (left panel), more than 80% of β5, β5i and β1i activities were 
blocked by Cfz for both H727 and H23 cells. On the contrary, over 50% of β1 activity 
62 
 
persisted in H727 cells, but not in H23 cells (Figure 3.5C, left panel). It remains 
unclear whether the remaining β1 activity contributes to de novo resistance of H727 
cells to Cfz. On the other hand, Btz treatment resulted in over 80% inhibition across 
all catalytic subunits in both H727 and H23 cell lines, which may explain the high 
sensitivity of both cell lines to Btz (Figure 3.5C, right panel). These results support 
that the 20S proteasomes present in H727 cells may be functionally different from 
those in Cfz-sensitive H23 cells.  
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Figure 3.5 Distinct composition of proteasome catalytic subunits in H727 cells  
A. Immunoblots showing the differential expression of cP and iP catalytic subunits in 
H727 and H23 cells as well as Cfz-sensitive panc-1 and RPMI 8226 cells. B. Differential 
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proteasome activity profiles in H727 and H23 cell lines. Purified human 20S cP and 
iP were used as controls for individual subunits: 20S cP for β5 and β1 and 20S iP for 
β5i and β1i. The numbers represent hydrolysis rates of respective substrates 
(RFU/min, mean values derived from three technical replicates) C. Remaining 
catalytic activities of individual proteasome subunits in H727 and H23 cells 4 h after 
treatment with 20 nM of carfilzomib (left panel) or 20 nM bortezomib (right panel). 
Data are presented as mean ± SD derived from three technical replicates.  
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3.3.5 A distinct composition of proteasome catalytic subunits in H727 cells 
Based on the differential expression pattern of proteasome catalytic subunits 
in H727 as compared to H23, we hypothesized that the composition of proteasome 
catalytic subunits may impact the sensitivity of H727 cells to Cfz. To test this 
hypothesis, we altered catalytic subunit composition in H727 using interferon-γ (IFN-
γ) treatment. IFN-γ’s ability to upregulate immuno-subunits (β1i, β2i, and β5i) and to 
induce IP formation has been well-documented [37, 38]. As shown in Figure 3.6A, 
incubation of H727 cells with IFN-γ (150 U⋅ml-1) 24 h prior to Cfz treatment resulted 
in upregulation of immune-subunit expression and corresponding increases in their 
activity. IFN-γ pre-treatment caused a significant decrease in Cfz IC50 values from 
621.1 to 189.5 nM in H727 cells. When H23 cells were pre-treated with IFN-γ, the Cfz 
IC50 values changed in the opposite direction (IC50 values increased from 18.6 to 44.1 
nM, Figure 3.6B). With IFN-γ pre-treatment, the fold differences in IC50 values 
between the two cell lines were reduced from 33-fold to 4.2-fold. Consistently, IFN-γ 
pre-treatment also had effect on viability of RPMI 8226 cells with acquired Cfz 
resistance. Human RPMI 8226 multiple myeloma cells with acquired resistance to Cfz 
were established by adapting them in the presence of escalating concentrations of Cfz 
up to 80 nM over 6 months. RPMI 8226 Cfz-resistant cells were cultured in 80 nM of 
Cfz and then grown in the absence of Cfz for two weeks prior to the use. We have 
observed the P-glycoprotein was overexpressed in RPMI 8226 Cfz-resistant cells 
(Data shown in chapter 4). Regardless of P-glycoprotein overexpression, IFN-γ (150 
U⋅ml-1) pretreatment could mediate the cellular response to Cfz (from 239.2 nM to 
135.1 nM) in this cell line. 
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Figure 3.6 Effect of IFN-γ pretreatment on H727 and H23 cells  
A. IFN-γ (150 U⋅ml-1) pretreatment for 24 h led to increased expression (top left 
panel) and activity (top right panel) of proteasome immuno-subunits. and sensitized 
H727 cells to Cfz (bottom) B. IFN-γ (150 U⋅ml-1) pretreatment for 24 h desensitized 
H23 cells towards Cfz. The IC50 values displayed a statistically significant difference 
between IFN-γ-pretreated cells and vehicle control in both of H727 and H23 cells. (P 
value < 0.01, n=3, Student’s t-test comparing the log transformed IC50 values obtained 
from three independent runs). 
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3.3.6 Alteration of proteasome catalytic subunit composition affects H727 Cfz 
sensitivity 
In order to further investigate a causal relationship between the composition 
of proteasome catalytic subunits and Cfz sensitivity, we sought to alter the 
composition of proteasome catalytic subunits in H727 cells in a more selective 
manner using an siRNA pool targeting the abundantly expressed β5 subunit. We 
expected that β5i will substitute for β5 during proteasome assembly, forming 20S 
complexes with altered catalytic subunit composition. When β5 was knocked down 
(verified via immunoblotting and activity assays, Figure 3.7A & B), H727 cells grew 
normally with modest upregulation of β5i. Despite their normal growth, H727 cells 
were significantly sensitized to Cfz by β5 knockdown, shifting the IC50 value from 622 
to 99.9 nM (Figure 3.7C). In contrast, the IC50 for Btz was only modestly affected, 
decreasing from 26 to 12 nM (Figure 3.7D). Knockdown of other catalytic subunits 
such as β5i and β2 resulted in minimal changes in the IC50 values for Cfz. A similar 
pattern was observed in H23 cells where knockdown of β5i and β2 had little effect on 
Cfz sensitivity but β5 knockdown triggered a five-fold reduction in Cfz IC50 from 26.7 
to 5.0 nM (Figure 3.7C).  
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Figure 3.7 The effect of catalytic subunit knockdown on H727 cells 
A. Immunoblots of proteasome catalytic subunits in H727 cells transfected with 
siRNA targeting β5, β2 or β5i. B. The catalytic activity of β5 subunit was decreased in 
H727 cells transfected with siRNA targeting β5 compared with H727 cells transfected 
with scrambled siRNA. C. Effects of siRNA knockdown of β5, β5i, or β2 on Cfz 
sensitivity (IC50 values) in H23 and H727 cells. Data are shown as mean ± SD derived 
from a non-linear regression based on n=3 replicates per compound per 
concentration. D. 72 h cell viability for Bortezomib 48 h after siRNA knockdown β5 in 
H727 cells  
70 
 
3.3.7 The proteasome activity profiles of primary MM cells is highly variable  
In order to assess whether the observed variability in proteasome activity 
profiles in PI-naıv̈e cell line models reflects the Cfz sensitivity of clinical MM samples, 
we examined the proteasome activity profiles and degree of Cfz sensitivity using 6 
MM samples from patients who have received no prior PI therapy. Similar to the 
results obtained using cell line models, the clinical samples also showed considerable 
variability in catalytic subunit activity profiles and Cfz sensitivity (Figure 3.8 A & B). 
Due to the limited sample quantities, we were not able to perform any further 
investigations on these samples. Based on these initial assessments, we cautiously 
speculate that differential Cfz sensitivity in these patient samples may be influenced 
by variability in proteasome catalytic subunit composition, perhaps partially 
accounting for the varied responses to Cfz observed in clinical trial results [260, 263, 
264].  
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Figure 3.8 Activity profile and viability for Cfz in primary MM samples 
A. Heat map showing proteasome catalytic subunit activity profiles of 6 PI-naïve 
patient MM samples purchased from Conversant Biologics and AllCells. The numbers 
represent hydrolysis rates of respective substrates (RFU/min, mean values derived 
from three technical replicates) and were converted to color format and clustered by 
using the program “R” (http://www.R-project.org) B. Carfilzomib (Cfz) cell viability 
of the same 6 patient MM cells was measured via CellTiter-Glo Luminescent Cell 
Viability Assay. 
 
  
A B 
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3.4 Discussion 
Cfz has contributed to a substantial advancement in multiple myeloma 
treatment by improving patient survival and quality of life. A considerable portion of 
patients however display intrinsic resistance to Cfz. A significant portions of MM 
patients previously treated with Btz-containing regimens do not respond to Cfz and 
even those who initially respond to Cfz almost ultimately develop resistance in the 
course of their treatment [260, 266]. In order to design new and effective therapeutic 
strategies to overcome resistance, it is important to better understand the 
mechanisms of Cfz resistance. To date, investigations of Cfz resistance have largely 
focused on acquired resistance due to the relative ease of generating Cfz-adapted 
cancer cell lines and the availability of clinical samples derived from patients who 
have developed resistance after prolonged Cfz therapy. On the other hand, 
mechanistic investigations of de novo Cfz resistance have been scarce, due to the lack 
of appropriate cell line models and patient samples. 
In the current study, we report that H727 cells are intrinsically resistant to Cfz, 
potentially serving as a useful model for mechanistic investigations of de novo Cfz 
resistance. Given that H727 cells were sensitive to inhibitors of non-proteasomal 
targets in the UPS and PIs other than Cfz, we surmise that H727 cells harbor 
functionally active proteasomes and that complete or near-complete inhibition of 
proteasome catalytic activity is incompatible with survival in these cells. Based on our 
current results, a shift towards non-UPS protein degradation pathways appears 
unlikely since H727 cells remain highly sensitive to the inhibition of UPS components 
including the proteasome itself.     
Despite their similar degrees of dependence on the proteasome or UPS for 
survival and growth, H727 and H23 cells respond differently to Cfz, to a degree of 33-
fold difference in IC50 values. This may be in part due to cell line-dependent cell 
growth rates or genetic/molecular differences. However, the high sensitivity of H727 
cells to other PIs suggests that Cfz resistance in H727 cells may be mediated at the 
20S proteasome level. It has been reported that proteasome inhibitor resistance is 
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often associated with increased levels of proteasome subunit catalytic activity, 
especially in models of acquired bortezomib resistance [117, 272]. However, H727 
cells displayed substantially low activities of individual catalytic subunits as 
compared to H23 cells. At present, it is unclear whether the low proteasome activities 
in H727 cells are involved in conferring Cfz resistance. Previously it was reported that 
20S proteasomes harboring a mixed assortment of cP and iP catalytic subunits exist 
in cancer cells and that their PI sensitivity differs from those of standard cP or iP5. 
Our results also indicated not only differing expression levels of proteasome catalytic 
subunits between H727 and H23 cells, but also differing levels of subunit catalytic 
activity. These findings are consistent with the presence of non-standard 20S 
proteasome subtypes (other than cP and iP). Determination of the 20S proteasome 
subtypes present in H727 cancer cells may shed further light on the underlying 
mechanisms of de novo Cfz resistance in H727 cells. Determination of the subunit 
composition of intact 20S proteasomes in cells is challenging and several groups 
including ours are currently trying to develop bi-functional or fluorescent probes to 
facilitate these efforts [273, 274]. 
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CHAPTER 4. DEVELOPMENT OF NOVEL EPOXYKETONE-BASED PROTEASOME 
INHIBITORS AS A STRATEGY TO OVERCOME CANCER RESISTANCE TO 
CARFILZOMIB AND BORTEZOMIB 
Some of the work in this chapter has been accepted in Journal of Medicinal 
Chemistry 2019 [334].  
 
4.1 Introduction 
In 2003, the FDA approval of first-in-class Proteasome inhibitor (PI) 
bortezomib (Velcade®, Btz) for treating patients with multiple myeloma (MM) 
validated the proteasome as an anticancer target.  A decade later, the FDA approved 
a second-in-class PI—carfilzomib (Kyprolis®, Cfz) and ixazomib (Ninlaro®, Ixz)—for 
treating patients with relapsed MM, firmly establishing the proteasome as an exciting 
target in treating cancer. Although the use of PIs in MM patients has successfully 
improved clinical outcomes, a subset of PI-naïve patients failed to respond to these 
inhibitors, and almost all patients who do respond eventually acquire PI resistance 
[105, 261, 263]. Recently, three non-PI drugs, daratumumab (a monoclonal antibody 
(mAb) targeting CD38), elotuzumab (mAb targeting SLAMF7) and panobinostat 
(HDAC inhibitor) were approved for treatment of relapsed MM. While these non-PI 
drugs provide additional options for MM patients relapsed on current PI-based 
therapies, a portion of patients still do not respond to these therapies. The results 
from recent clinical trials show that the response for these non-PI drugs is rather 
transient with the median duration of ~7-20 months before relapsing [275-277]. 
Therefore, it is now critically important to develop new therapeutic strategies that 
can overcome the limitations of the FDA-approved PIs and deliver the therapeutic 
benefits of PIs to cancer patients who have exhausted current treatment options.  
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The ubiquitin proteasome system (UPS) remains essential for cancer cells 
regardless of resistance to existing PI drugs. The UPS upstream components of the 
proteasome such as ubiquitin E3 ligases and deubiquitinases are being explored as 
potential anti-cancer therapeutic targets [245, 246, 278], but not be successful yet. 
Alternatively, it remains to be seen whether the proteasome itself can be 
subsequently re-targeted to achieve further therapeutic gains for MM patients 
relapsed on existing PI drugs.  
Most of PIs have been developed through medicinal chemistry approach, 
optimizing amino acid side chains (P1, P2, P3) which interact with the substrate 
binding pockets (S1, S2, S3, etc.) of proteasome catalytic subunits. This binding 
configuration is further stabilized by anti-parallel β-sheet conferring hydrogen 
bonding interactions between the inhibitor’s peptide backbone and conserved 
residues such as Thr21, Gly47, and Ala49 of proteasome catalytic subunits [279-281]. 
When combined with a C-terminal warhead which targets the catalytic Thr1 residue, 
this strategy typically yields potent inhibitors including the three FDA-approved PIs: 
Btz, Ixz (peptide boronic acids) and Cfz (a peptide epoxyketone). However, this 
strategy might have unintentionally contributed to an increased cross-resistance 
among them. A potential strategy to overcome PI cross-resistance is to identify and 
exploit a structural niche not utilized by existing PIs. In that regard, previously 
unexplored are P1′ binding sites which lie on the C-terminal side of the proteasome 
catalytic subunit’s cleavage site. 
Here, we have developed peptide epoxyketones having a P1′-targeting moiety. 
The anticancer efficacy of these compounds was superior to their non-P1′-targeting 
parent compounds when evaluated against models of intrinsic and acquired Cfz 
resistance. The identified lead compound, Cfz-OH, an analog of Cfz containing a 
hydroxyl group at the P1′ position, displayed potent proteasome inhibitory activity 
and cytotoxicity in both Cfz-sensitive and Cfz-resistant cancer cell lines. 
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4.2 Material and Methods 
4.2.1 Chemistry 
Peptide epoxyketones having a P1′-targeting moiety were synthesized by Dr. Deepak 
Bhattarai. 
 
4.2.2 Enzyme kinetic assay 
Purified human 20S immunoproteasome (Boston Biochem) or RPMI 8226 cell lysates 
were diluted in 20S proteasome assay buffer (20 mM Tris-HCl, 0.5 mM EDTA, 0.035% 
SDS, pH 8.0) and incubated with various concentrations of each inhibitor for 1 h in a 
96-well plate. The fluorogenic substrates Suc-Leu-Leu-Val-Tyr-AMC (Bachem) or Ac-
Pro-Ala-Leu-AMC (Boston Biochem) were used at the final substrate concentration of 
100 μM to measure the remaining levels of chymotrypsin-like activity or LMP2-
specific catalytic activity, respectively. Fluorescence signals from the release of free 
AMC (7-amino-4-methylcoumarin) were monitored every minute for 1 h via a 
SpectraMax M5 microplate reader (Molecular Devices) using excitation and emission 
wavelengths of 360 and 460 nm, respectively. The initial hydrolysis rates (slopes) for 
individual wells were calculated via linear regression and normalized to the values 
from vehicle-treated control wells. Non-linear regression analysis was performed 
using GraphPad Prism 7 to calculate an IC50 value for each compound in inhibiting 
proteasomal CT-L or LMP2 activity. 
 
4.2.3 Cell culture 
Human cancer cell lines H23, H727, and RPMI8226 were obtained from the ATCC 
(American Type Culture Collection) and maintained in the ATCC recommended media, 
RPMI1640 supplemented with 10% fetal bovine serum (Gibco, and Atlanta 
Biologicals). RPMI8226 cells with acquired resistance to Cfz were established by 
adapting them in the presence of stepwise increasing concentrations of Cfz up to 80 
nM over a period of approximately 6 months. Cfz-resistant cells were maintained in 
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80 nM Cfz and then grown in the absence of Cfz for approximately one week prior to 
the experiments.  
 
4.2.4 Isolation of primary MM samples 
Bone marrow (BM) aspirates were obtained from patients after approval by the UC 
Cancer Institute Institutional Review Board followed by positive selection with 
CD138 microbeads developed for the isolation of plasma cells. Immunophenotyping 
by flow cytometry was performed to confirm the purity and quantity of selected 
CD138+ plasma cells. 
 
4.2.5 Cell Viability 
4.2.5.1 Established cancer cell lines 
H23 cells or H727 cells were plated at 5,000 or 10,000 cells per well, respectively. 
RPMI8226 cells and Cfz-resistant RPMI8226 sublines growing in suspension were 
plated at 10,000 cells per well. Twenty-four hours after plating, media containing the 
test compounds were added to each well to deliver the intended final concentration. 
After 72 h, cell viability was determined using the assay protocol recommended by 
the manufacturer (CellTiter 96 Aqueous One Solution Cell Proliferation assay, 
Promega). The resulting signals were measured using a SpectraMax M5 microplate 
spectrophotometer (Molecular Devices). Non-linear regression analysis was 
performed using GraphPad Prism 7 to calculate an IC50 value for each compound to 
incur cell death. 
4.2.5.2 Primary MM cells 
Purified primary MM cells were plated on 96-well plates at a density of 20,000 cells 
per well in IMDM media (Gibco) supplemented with 10% FBS. After cells were treated 
with test compounds for 48 h, the percentage of viable cells was determined using the 
CellTiter Glo Luminescent Cell Viability Assay (Promega) and a Veritas microplate 
luminometer (Promega). 
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4.2.6 Immunoblotting 
Cell lysates were prepared using ice-cold RIPA lysis buffer (50 mM Tris–Cl, 150 mM 
NaCl, 1% NP-40, 1% Triton X-100) supplemented with 1% protease inhibitor cocktail 
(Sigma–Aldrich). After centrifugation at 14,000g at 4 °C for 20 min, the resulting 
supernatant was collected and subject to the total protein assay using Protein Assay 
Dye Reagent Concentrate (Bio-Rad). Proteins were resolved by 7.5% SDS-PAGE, and 
transferred onto PVDF membranes (Bio-Rad) via semi-dry transfer. After blocking in 
5% nonfat dry milk, membranes were incubated with primary antibodies (anti-P-gp 
(Abcam) or anti-β-actin (Enzo)) at 4 °C overnight. Membranes were washed and 
incubated with appropriate peroxidase-conjugated secondary antibodies for 1 h at 
room temperature. Proteins were visualized on Kodak BioMax XAR Films (Sigma– 
Aldrich) using ECL.  
 
4.2.7 In vitro metabolic stability 
To assess whether Cfz-OH has indeed an improved metabolic stability over Cfz, we 
compared the rate by which Cfz-OH or Cfz disappears in the presence of rat liver 
homogenates, as previously reported [282]. Briefly, the liver was obtained from male 
Sprague-Dawley rats (8 week-old, Nara Biotech Co. Ltd., Seoul, Korea) using the 
protocol approved by the Seoul National University Institutional Animal Care and Use 
Committee (approval No. SNU-160512-5-1). The harvested liver was washed with 
phosphate-buffered saline (PBS, pH 7.4) and homogenized using 5-fold excess volume 
of PBS per g tissue. After pre-incubation at 37 °C, an aliquot of liver homogenates was 
spiked with the stock solution of Cfz or Cfz-OH to achieve the final concentration of 1 
M (total volume of 400  µl, n=3). At the pre-designated time (0, 5, 10, and 20 min), an 
aliquot (40 µl) was collected and mixed with 4-fold excess volume of ice-cold 
acetonitrile containing chlorpropamide (an internal standard, IS, 0.5 µM). After 
vortexing and centrifugation, the drug levels in the resulting supernatant were 
analyzed via HPLC interfaced with mass spectrometry (LC-MS/MS).  
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Cfz-OH was quantified using the slightly modified analytical conditions via LC-MS/MS 
(1260 infinity HPLC system interfaced with 6430 Triple Quad LC-MS system, Agilent 
Technologies, Palo Alto, CA) in a positive ion mode. The chromatic separation was 
performed using a Poroshell 120 EC-C18 column (4.6 x 50 mm, 2.7 µm, Agilent 
Technologies, Palo Alto, CA) and an isocratic mobile phase composed of acetonitrile 
and water (75:25, v/v) at a flow rate of 0.3 mL/min. The retention time of Cfz-OH was 
1.7 min and the gas temperature was set at 300 °C. The source-dependent parameters, 
the fragment voltage, collision energy and cell accelerator voltage were set as follows: 
170 V, 75 V, and 1 V for Cfz-OH and 90 V, 30 V and 7 V for chlorpropamide (IS). 
Quantification was performed in the selected reaction monitoring (SRM) mode using 
the following transitions: m/z 736.2 > 99.9 for Cfz-OH and m/z 276.9 > 110.8 for 
chlorpropamide (IS). The calibration samples were prepared in the range of 1 to 200 
nM and the signals showed linearity with the r2 value greater than 0.98. The data 
were processed using the MassHunter Workstation Software Quantitative Analysis 
(vB.05.00; Agilent Technologies). 
4.3 Results 
4.3.1 Initial screening for proteasome inhibitors that overcome intrinsic Cfz resistance 
As described in chapter 3, H727 human lung adenocarcinoma cell line is 
intrinsically resistant to Cfz (IC50 of 611 nM) compared to a panel of cancer cell lines 
(IC50’s in the low nM range). Thus, we selected the H727 cell line as our cell line model 
of intrinsic resistance to Cfz in which to identify PIs that can overcome de novo 
resistance to Cfz.  As a control, we used another lung cancer cell line model of H23 
cells, which are highly sensitive to Cfz (IC50 of 18 nM). We treated theses Cfz-sensitive 
H23 and Cfz-resistant cancer H727 cell lines with PIs that have distinct chemical 
structures and pharmacophores—The peptide epoxyketone inhibitor carfilzomib, the 
peptide boronate inhibitor bortezomib, the peptide aldehyde inhibitor MG-132, the 
in-house-generated peptide epoxyketone inhibitors UK-101 and UK-102, and the β-
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lactone inhibitor lactacystin (Figure 4.1)—for 72 hours. We then measured the effects 
of each inhibitor on cell viability.  UK101 and UK102 were previously developed in 
our laboratory [283]. Interestingly, compared to Cfz, UK-101 and UK-102, displayed 
relatively smaller differences in their IC50 values between Cfz-sensitive and Cfz-
resistant cancer cells (Table 4.1). In other words, UK101 and UK102 displayed a 
comparable cytotoxicity in H727 and H23 cells. In addition, Cfz-resistant cancers may 
be minimally cross-resistant to UK-101 and UK-102. On the other hand, a β-lactone 
inhibitor lactacystin was not as effective in H727 cells as in H23 cells. These results 
suggest that targeting the proteasome using alternative PIs still can be a viable 
therapeutic option even in the presence of cancer resistance to Cfz and Identifying 
alternative PIs that remain effective in Cfz-resistant cancer cells.  
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Figure 4.1 Structures of structurally distinct-proteasome inhibitors  
Structures of the peptide epoxyketone inhibitor carfilzomib, the peptide boronate 
inhibitor bortezomib, the peptide aldehyde inhibitor MG-132, the β-lactone inhibitor 
lactacystin, and the in-house-generated peptide epoxyketone inhibitors UK-101 and 
UK-102 are shown 
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Table 4.1 Cytotoxicity of proteasome inhibitors in H727 and H23 cells 
 
IC50 (µM) 
H23 H727 
Fold difference 
(H727/H23) 
Carfilzomib 0.018 ± 0.004 0.611 ± 0.047 33.3 
Bortezomib 0.010 ± 0.001 0.025 ± 0.006 2.5 
MG-132 0.48 ± 0.01 0.98 ± 0.03 2 
Lactacystin 5.23 ± 0.22 > 100 > 19 
UK101 3.37 ± 0.19 5.21 ± 0.11 1.5 
UK102 3.40 ± 0.18 4.49 ± 0.26 1.3 
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4.3.2 The PIs with P1’ (UK101 & UK102) exert the anticancer efficacies in acquired Cfz 
resistant cancer cells 
 
Since acquired cfz resistance is a major clinical challenge facing Cfz-based 
therapies, we wondered whether these P1′-targeting epoxyketones, UK101 and 
UK102 are also effective in acquired Cfz resistance cells. To test this, we established 
a Cfz-resistant subline of human MM RPMI8226 and U266 (RPMI 8226/CfzR and 
U266/CfzR) by culturing them in the continuous presence of gradually increasing 
concentrations of Cfz over 6 months. As shown in Figure 4.2 A&B, results from MTS 
cell viability assays revealed that, in comparison with those of their respective 
parental cell lines, the Cfz IC50 values of RPMI 8226/CfzR and U266/CfzR cells were 
36-fold and 9-fold higher, respectively. 
As described previously, several studies have shown that the efflux 
transporter P-gp can contribute to acquired resistance to Cfz observed in cancer cell 
line models and clinical samples from patients with prior Cfz therapy [132-135]. To 
test whether P-gp plays a role in these RPMI 8226/ CfzR and U266/ CfzR cell line 
models, we performed immunoblotting analysis to detect P-gp expression (Figure 
4.3A). While there is no delectable level of P-gp expression in PRMI 8226 or U266 
parental cells, the highly elevated expression of P-gp in both RPMI 8226/CfzR and 
U266/CfzR cells. Furthermore, treatment of RPMI 8226/CfzR cells with 7.5 µM of 
reversin 121, a dipeptide P-gp inhibitor, did not significantly impact the IC50 value of 
Cfz (Figure 4.3B), confirming the predominant contribution of P-gp in the current 
model of acquire Cfz resistance. Using these acquired Cfz resistant cell line modesl, 
we examined the effectiveness of P1′-targeting epoxyketones. As reported before, 
both epoxyketone PIs Cfz and epoxomicin displayed a marked increase in IC50 values, 
indicating there are P-gp substrate. On the other hand, compared to Cfz, UK-101 and 
UK-102, displayed relatively smaller differences in their IC50 values between Cfz- 
resistant cancer cells and their parental controls (Table 4.2). 
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Figure 4.2 Establishment of MM cell lines with acquired resistance to Cfz 
A. 72 h cell viability data for Cfz in RPMI 8226 parental and Cfz-resistant cells are 
shown. B. 72 h cell viability data for Cfz in U266 parental and Cfz-resistant cells are 
shown. 
  
A B 
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Figure 4.3 P-gp overexpression in acquired Cfz resistant MM cells  
A.  Immunoblotting results showing elevated expression of P-glycoprotein (P-gp) in 
RPMI 8227 and U266 cells with acquired Cfz resistance. B. The co-treatment of 
reversin-121 (7.5 µM, P-gp inhibitor) restored the sensitivity of RPMI 8226/CfzR cells 
to Cfz. Data shown are representative of biological triplicate experiments. 
 
  
A 
B 
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Table 4.2 Cytotoxicity of proteasome inhibitors in acquired Cfz resistant cells 
 
IC50 (nM) 
RPMI 
8266 
RPMI 
8266/CfzR 
U266 U266/CfzR 
Carfilzomib 7.4 ± 1.5 269.8 ± 55.6 8.9 ± 1.1 73.7 ± 10.4 
Epoxomicin 11.3 ± 5.9 540.9 ± 58.0 ND ND 
UK101 
2147 ± 
803 
3728 ± 105 1818 ± 891 7096 ± 844 
UK102 
1753 ± 
113 
9651± 902 1809 ± 109 1284 ± 114 
 
Data are reported as the mean ± SD. For epoxomicin and carfilzomib, the SD values 
were obtained from three independent experiments. For UK101 and UK102, the SD 
values were from non-linear regression analysis using three replicates.   
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4.3.3 UK101 and UK102 exert the anticancer efficacy in acquired Btz resistant-
primary MM samples 
 
In order to further validate that UK-101 and UK-102 have anticancer efficacy 
in Cfz-resistance, we examined whether UK101 and UK102 can be also effective in 
primary MM samples derived from patients who do not respond to Btz.  Since we were 
unable to obtain MM samples from patients who are resistant to Cfz, we only obtained 
primary cells from two different patient groups: patients who did not respond to Btz 
therapy (Btz-resistant patients), and patients who were never treated with Btz or Cfz 
(PI-naïve patients), but it was previously reported that patients with MM refractory 
to or relapsed on Btz are often cross-resistant to Cfz [260]. Using the primary MM 
samples from 14 different donors (6 from PI-naïve patients and 8 from patients 
relapsed on Btz therapy), we treated these primary MM cells for 48 hours with Cfz, 
UK-101, or UK-102 at its in vitro IC80 concentration derived from viability assay in cell 
line models via CellTiter-Glo® Luminescent Cell Viability Assays. In this assay, we 
found varying degrees of sensitivity to Btz or Cfz, but the MM samples from the 
patients who relapsed on Btz tended to be less responsive to both Btz and Cfz than 
those from patients from the PI-naïve group (Figure 4.4 A & B). Due to limited 
quantities of primary MM samples from 6 patients (#1-#4, #9, and #10), we only 
utilized 10 primary MM samples (4 Btz-resistant and 6 PI-naïve) to examine the 
efficacy of UK101 or UK102. When 10 primary MM samples treated with UK101 or 
UK102 for 48 h, the results showed UK-101 and UK-102 remained much more active 
in primary MM cells derived from Btz-resistant patients and the PI-naïve patients in 
a dose dependent manner (Figure 4.4 C & D). These results suggest that alternative 
PIs such as UK-101 and UK-102 may have valuable clinical potential and warrant 
further investigation. Furthermore, the lack of apparent cross-resistance between 
Cfz/Btz and UK101/UK102 was encouraging although the current sample size was 
small. 
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Figure 4.4 Cytotoxic effects of bortezomib, carfilzomib, UK101, and UK102 on 
primary MM samples 
A.  Viability for 50 nM of Btz in primary MM cells derived from Btz-resistant patients 
and PI-naïve patients B. Viability for 50 nM of Cfz in primary MM cells derived from 
Btz-resistant patients and PI-naïve patients C. Viability for 10 or 15 µM UK-101 in 
primary MM cells derived from Btz-resistant patients and PI-naïve patients D. 
Viability for 10 or 15 µM UK-102 in primary MM cells derived from Btz-resistant 
patients and PI-naïve patients.  
A B 
C D 
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4.3.4 Introduction of hydrophilic residues at the P1’ position of peptide epoxyketones 
enhances the potency of the proteasome inhibition. 
 
Since we observed that UK101 and UK102 had anti-cancer efficacy in primary 
samples derived from Btz-resistant patients but displayed display much lower 
potencies than Btz and Cfz with IC50 values, we first utilized a previously reported 
docking model of UK101 bound to β1i and β5, known targets of UK101 to improve 
the potency of UK101/UK102 and obtain structure-activity relationship (SAR) 
information [84, 283].  As shown in Figure 4.5, the P1-P3 residues of UK101 were 
predicted to occupy the S1-S3 pockets located deep inside of the active sites of the β1i 
and β5 subunits. However, unlike Cfz bound to β5, docking followed by molecular 
dynamics simulations indicated that UK101 occupies an additional binding pocket 
(S1′) of the β5 as well as β1i subunits via its P1′ group (highlighted in purple circles, 
Figure 4.5) which is not occupied by Cfz or Btz. Although the P1′ group (t-
butyldimethylsilyl, TBDMS) of UK101 is not predicted to participate in any specific 
interactions upon binding to β1i, it fully occupies the S1′ pocket defined by the 
surrounding polar amino acids (Ser21, Ser48, Ser95, His97). In the case of UK101 
bound to β5, a steric clash between the TBDMS group and Tyr169 is noted. The 
resulting change in conformation is predicted to abolish a potential hydrogen bond 
between UK101 and Gly47, a plausible contributing factor towards UK101’s low 
potency against the β5 subunit [284]. We hypothesized that the optimization at the 
P1′ position could provide energetically-favorable interactions with the S1′ pocket of 
β1i and also avoid steric clash with Tyr169 of β5, potentially improving potency 
against both subunits. To test this, we replaced the bulky hydrophobic P1′ substituent 
(TBDMS) of UK101 with a hydroxyl group (scheme in Figure 4.6) and assessed its 
impact. This simple P1′ substitution increased in vitro 20S proteasome inhibitory 
potency by ~4-10 fold (Table 4.3). Moreover, the P1′ hydroxyl group also 
considerably improved the cytotoxic activity of UK101-OH (5) cancer cell lines, 
including our models of both de novo and acquired Cfz resistance. Based on this result, 
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we suspect that the P1’ residue of peptide epoxyketones may play an important role 
in overcoming the resistance of cancer cells to Cfz. 
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Figure 4.5 Predicted docking models of UK101 and Cfz bound to β5 or β1i 
Predicted docking models of UK101 and carfilzomib (Cfz) bound to β5 or β1i. The 
superposition of the β5 and β1i active sites are shown based on molecular dynamics 
simulations. The location of UK101’s TBDMS group positioned within putative P1′ 
pockets is highlighted using a purple-colored circle. X-ray structures of β1 (PDB ID: 
3UNF) and β5/X (PDB ID: 3UNE) from mammalian 20S proteasomes were used as 
templates for modeling LMP2 and X. This experiment was performed by Dr. Chang-
Guo Zhan’s group in the College of Pharmacy, University of Kentucky. 
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Figure 4.6 Synthetic scheme for UK101-OH (5) 
These compounds including UK101-OH(5) were synthesized by Dr. Deepak Bhattarai. 
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 Table 4.3 Cytotoxicity of proteasome inhibitors in H727, H23, RPMI 8226/CfzR 
cells 
Data are reported as the mean ± SD.  
  
Proteasome 
inhibitors 
IC50 (µM) 
CT-L LMP2 H23 H727 
RPMI 
8266/CfzR 
UK101 > 10 
0.140 ± 
0.01 
3.37 ± 
0.19 
5.21 ± 
0.11 
2.14 ±  
0.08 
5  
(UK101-OH) 
1.7 ±  
0.1 
0.036 ± 
0.01 
0.58 ± 
0.02 
0.69 ± 
0.01 
0.31 ±  
0.01 
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4.3.5 Development of Cfz analog with an improved potency in de novo and acquired 
Cfz resistant models 
 
In our efforts to further optimize UK101-OH, we deemed that the P1-P4 groups 
of Cfz have already been thoroughly optimized for the S1-S4 pockets of β5 and β5i (as 
well as β1i, to a lesser extent, based on the largely β1i/β5 superimposed model, 
Figure 4.5). We thus decided to attach several different P1′ moieties to Cfz. Since we 
have observed that Cfz analogs bearing a P1′-targeting group could overcome cross-
resistance to Cfz, we also expected that a Cfz analog containing a polar P1′ moiety 
leading an improved inhibitory potency against both β5 and β1i compared to Cfz, due 
to additional P1′:S1′ interactions. Based on this, we prepared Cfz analogs having a 
series of P1′ moieties varying from bulky hydrophobic to small hydrophilic residues 
(synthetic scheme in Figure 4.7). We subsequently measured their activity against 
cell lysates to measure CT-L (β5/β5i) inhibition and against 20S purified 
immunoproteasomes to measure β1i inhibition. As predicted by molecular dynamics, 
Cfz-OH and Cfz-Sulfone having small polar moieties were most potent in vitro with 
IC50 values similar to that of Cfz. When these two compounds were tested using Cfz-
resistant H727 cells, Cfz-Sulfone (12) was less potent than Cfz against H727. On the 
other hand, Cfz-OH, a Cfz analog (9) with a hydroxyl group at the P1′ position, 
demonstrated an improved potency by ~10-fold relative to Cfz. When tested against 
RPMI8226 with acquired Cfz resistance, Cfz-OH (9) demonstrated an almost 3-fold 
improvement in potency against Cfz-resistant RPMI8226 cells as compared to Cfz 
(Figure 4.8).  
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Figure 4.7 Synthetic scheme for Cfz-OH (9) 
These compounds including Cfz-OH (9) were synthesized by Dr. Deepak Bhattarai. 
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Figure 4.8 Effects of various substitutions at the P1′site of the compound on the 
potency in Cfz resistant cells  
The potency (IC50 values) for compounds with various substitutions at the P1′site 
against proteasome chymotrypsin-like activity (RPMI8226 cell lysate), LMP2 activity 
(purified human 20S immunoproteasome), and cell viability of H23, H727, and Cfz-
resistant RPMI8226 cells. Data reported as the mean ± SD (carfilzomib, n = 3 
independent experiments) or from a single experiment (3 replicates, 7, 9, and 12). 
 
 
  
97 
 
4.3.6 Cfz-OH has improved metabolic stability compared to Cfz 
 
Due to the presence of peptidase and microsomal epoxide hydrolase (mEH) enzymes 
throughout many of the body’s tissues, the peptide epoxyketone inhibitor carfilzomib 
is metabolized extremely rapidly, likely contributing to poor activity against solid 
tumors [285-287]. While cytochrome P450 is well known as a major enzyme to 
metabolize most of drugs, metabolites formed via P450 enzymes were only detected 
at very low levels. An in vitro study using rat tissue homogenates has confirmed that 
carfilzomib metabolism is not restricted to the liver and that lung, kidney, and heart 
tissues all possess the ability to rapidly degrade carfilzomib to its inactive metabolites. 
In the case of mEH, the active site harbors two conserved Tyr residues which may 
contribute to substrate specificity and orientation of substrates within the active site 
[288, 289]. The prototypical substrates of mEH include planar hydrophobic 
compounds such as various epoxides of polycyclic aromatic hydrocarbons and 
steroids [290]. It is thus expected that the epoxide ring of Cfz occupies the active site 
of mEH with a position suitable for hydrolysis to yield Cfz-diol (Figure 4.9). We 
hypothesized that the addition of a hydroxyl group adjacent to the epoxide ring of Cfz, 
Cfz-OH, may hinder the hydrolysis of the epoxide ring by inhibiting access to the 
active site of mEH. To assess whether Cfz-OH has indeed an improved metabolic 
stability over Cfz, we compared the rate by which Cfz-OH or Cfz disappears in the 
presence of rat liver homogenates, as previously reported [282]. In the presence of 
rat liver homogenates, Cfz-OH was metabolized much more slowly than Cfz. In this 
case ~40% of Cfz-OH remained unmetabolized at 5 minutes as compared to just 7% 
of carfilzomib (Figure 4.9). Based on these preliminary results we found Cfz-OH was 
indeed more stable than Cfz. 
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Figure 4.9 The metabolic stability of CFZ-OH 
A.  Schematic depicting the rapid metabolism of Cfz by microsomal epoxide hydrolase 
(mEH) to the inactive diol. B. Quantification of the remaining levels of Cfz or 9 
following the incubation with rat liver homogenate containing active mEH and 
peptidase activities for 5, 10, and 20 minutes respectively. Data presented as mean ± 
SD. This experiment was performed by Zi Soo Yoo from Wooin’s group in the College 
of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National 
University, Korea.  
A 
B 
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4.4 Discussion 
It is now well-understood that proteasome inhibitor resistance, either de novo 
or acquired, is a major limitation associated with the clinical use of PI drugs in treating 
cancers. In patients with refractory/relapsed MM, response rates for Btz and Cfz are 
less than 50% and 25%, respectively. Although the response rates can increase to 
~70-90% when combined with other drugs including lenalidomide, all patients 
inevitably develop resistance to therapy and have a dismal prognosis once resistance 
emerges. While several PI resistance mechanisms have been proposed so far, their 
clinical relevance is yet to be validated. Currently, the lack of the mechanistic 
understanding of PI resistance is a major obstacle in improving MM patient care.   
Mounting evidence has demonstrated that the proteasome remains necessary 
for cancer cells survival regardless of their resistance to PI drugs. The proteasome 
plays important roles in various cellular functions and to date there appears no 
pathway which can fully compensate for the loss of proteasome function. Several 
reports supported that proteasome inhibition may offer therapeutic gains even in 
patients with MM relapsed/refractory to currently used PIs in clinic.  
In this study, we used two type of PI resistant cancer cell lines, de novo Cfz 
resistant H727 cells or acquired Cfz resistant RPMI 8226/CfzR, U266/CfzR cells. We 
identified an effective proteasome inhibitor compound against both de novo or 
acquired Cfz resistant cell lines. We found that epoxyketones with P1′ substituents 
can overcome both de novo and to a lesser degree, acquired Cfz resistance in cell line 
models. It is well known peptide epoxyketones harbor greater selectivity in their 
interactions with the proteasome catalytic subunit by forming an 1,4-oxazepane 
adduct with the N-terminal catalytic threonine residue of the proteasome [75], 
leading to the improved safety profiles of Cfz over other classes PIs including the 
peptide boronate Btz. We believe that the compound with improved metabolic 
stability and ability to overcome resistance mechanisms may offer valuable 
knowledge for further drug development. Future studies will address the in vivo 
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efficacy and metabolic stability of epoxyketones with previously underexplored P1′ 
substituents that can overcome both de novo and acquired Cfz resistance. 
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CHAPTER 5. A SELECTIVE INHIBITOR OF THE IMMUNOPROTEASOME SUBUNIT 
LMP2 ATTENUATES DISEASE PROGRESSION IN MOUSE MODELS OF 
ALZHEIMER’S DISEASE  
Some of the work in this chapter has been submitted to Nature Chemical Biology. 
5.1 Introduction 
  Alzheimer’s disease (AD), the most common form of dementia, is a 
degenerative disorder of the brain that leads to memory loss. AD is a progressive, 
neurodegenerative disorder and is the sixth-leading cause of death across all ages. 
Currently there is there is no cure for AD, however, promising research and 
development for early detection and treatment is underway. Over the past decades, 
new therapeutic approaches targeting amyloid-β (Aβ) have been discovered and 
developed with the hope of modifying the natural history of AD. However, none of 
these drugs resulted in the positive cognitive improvement in most recent high-
profile phase III clinical trials [171], raising the doubt about amyloid hypothesis. In 
addition to extracellular Aβ, intraneuronal neurofibrillary tangles (NFT) composed of 
hyperphosphorylated tau protein have been also identified as a major hallmark of AD, 
leading active development of AD therapies targeting tau aggregation. Unfortunately, 
anti-tau therapies are also not available yet [291]. Therefore, it is highly timely and 
important to design disease-modifying drugs that are not reliant on the amyloid or 
tau hypothesis and to validate their therapeutic potential in pre-clinical and clinical 
studies. 
The 26S proteasome, an evolutionarily-conserved multiprotease complex, is 
largely responsible for controlled degradation of intracellular proteins, ranging from 
defective ribosomal products (DRiPs) to signaling proteins regulating numerous 
cellular processes (e.g., cell cycle control, immune response, apoptosis, stress 
response)[292]. Once poly-ubiquitinated, substrate proteins are recognized by the 
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19S regulatory particle and degraded by the 20S core particle of the 26S proteasome. 
In response to cellular stress or pro-inflammatory cytokines such as TNF-α or 
interferon (INF)-γ, cells upregulate variant forms of proteasome catalytic subunits, 
known as immuno-subunits (β1i/LMP2, β2i/MECL-1, β5i/LMP7). The resulting 
immunoproteasome (IP) harbors the immuno-subunits LMP2 and MECL-1 and LMP7 
instead of constitutive counterparts Y, Z and X, respectively. 
A previous study demonstrating the depletion of immunoproteasomes 
showed major changes in antigen presentation, indicating a fundamental role of the 
IP in antigen presentation by major histocompatibility complex (MHC) I class [293]. 
In addition, the IP also manages oxidative stress via degradation of misfolded and 
oxidant-damaged proteins [45]. In addition, LMP7, an immunoproteasome subunit, 
has been considered as an attractive therapeutic target for autoimmune disease due 
to the ability of regulating pro-inflammatory cytokine production in human tissues 
(T-cells, B-cells, neutrophils, monocytes etc)[52-57, 80]. LMP7-selective inhibitors 
(ONX0914, KZR-616) are currently in early phase clinical development for the 
treatment of rheumatic diseases, such as lupus nephritis (LN). For LMP2, there have 
been a few reports suggesting its involvement in processing of NFκB precursors 
(p100/p105) and degradation of IκBα [58-60]. However, recent studies dispute the 
involvement of LMP2 in inflammatory responses [56, 294 295]. 
Increasing evidence support an important role of inflammation in AD, thus 
many efforts to develop anti-inflammatory drugs targeting inflammation yielded 
several COX or TNF-α inhibitor for AD treatment. However, there is no clinically 
available AD therapies relied on inflammation so far [190]. While the role of IP in 
neuroinflammation is not clearly understood, it has been observed the elevated 
expression and activity of IP is correlated with enhanced microglial activation in AD 
patients and in a mouse model of brain injury [240-243]. Most recently, Wagner et al. 
reported LMP7 knockout improved cognitive impairment in a mouse model of Aβ 
deposition through altering microglial cytokine production profiles, suggesting a 
potential role of IP in Aβ-induced neuroinflammation [51]. In addition, moderate up-
regulation of LMP2 expression in AD patients was also reported [244]. Despite these 
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data suggesting the involvement of IP in neuroinflammatory responses and 
therapeutic potential for AD treatment, the pharmacological inhibition of LMP7 or 
LMP2 has never been tested for the impact on AD pathology.  
In this study, we investigated the effect of LMP2 inhibition on the symptom of 
AD, cognitive dysfunctions, in two different AD mouse models, LPS-induced 
inflammation model and APP transgenic mouse model. We found that a peptide 
epoxyketone inhibitor YU102 targeting LMP2 improved cognitive function in both of 
AD mouse models. These results were not affecting Aβ deposition or tau aggregation 
in a mouse model. Our in vitro cell line model data also showed YU102 suppresses 
production of pro-inflammatory cytokines. In summary, YU102 improves cognitive 
dysfunction by inhibiting pro-inflammatory cytokine production in microglial cells 
and these findings suggest that LMP2 may offer a valuable therapeutic target for AD 
treatment. 
 
5.2 Material and Methods 
5.2.1 Cells  
BV-2, EOC BV-2, EOC-20, and WI-38 cells were seeded at 5,000 cells/well and RPMI 
8226 cells. The murine microglial BV-2 cell line was a kind gift of Dr. Jin Tae Hong 
(College of Pharmacy, Chungbuk National University, Korea). The murine microglial 
cell line EOC-20, a human myeloma cell line RPMI 8226, and a human lung fibroblast 
cell line WI-38 cell line were obtained from American Type Culture Collection. BV-2 
cells were cultured in DMEM containing 10 % fetal bovine serum, and 1 mM pyruvate. 
All other cells were cultured according to the manufacturer’s protocol in 5% CO2 in 
medium. Cultured cell lines were tested for Mycoplasma contamination routinely 
every 2 months. BV-2 cells or EOC-20 cells were seeded at 2.5 × 105 cells/mL in 12-
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well plates and were activated by incubation in medium containing 1 µg/mL of E. coli 
055:B5 lipopolysaccharide (Thermo Scientific).  
 
5.2.2 Animals 
For YU102 efficacy studies, 9-month-old Tg2576 and 8-week-old ICR mice were 
purchased from the Division of Laboratory Animal Resources (Korea FDA, Osong, 
South Korea) and Samtako (Osan, South Korea), respectively. All animal studies were 
approved by Animal Care and Use Committee (IACUC) of Chungbuk National 
University (approval number: CBNUA-144-1001-01). Animals were housed three per 
cage, allowed access to water and food ad libitum, and maintained on a 12-h 
light/dark cycle regulated at 23°C. Experiments were performed at least 1 week after 
their arrival in individual home cages.  
 
5.2.3 Animal behavioral analysis 
5.2.3.1 The Morris watermaze test 
The Morris water maze test was performed following a procedure described 
previously [296]. Briefly, a circular plastic pool was filled with water maintained at 
22-25℃. An escape platform was submerged 1-1.5 cm below the surface of the water. 
The learning trials were conducted over 5 days, with three randomized starting 
points. The position of the escape platform was kept constant. Each trial lasted for 60 
sec or ended as soon as the mice reached the submerged platform. Swimming pattern 
of each mouse was monitored and recorded by a camera mounted above the center 
of the pool, and the escape latency, escape distance and swimming speed were 
assessed by the SMART-LD program (Panlab, Spain). A quiet environment and 
constant water temperature were maintained throughout the experimental period. 
To assess memory consolidation, a probe test was performed 24 hr after the water 
maze test (i.e. Day 6). For the probe test, the platform was removed from the pool and 
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mice were allowed to swim freely. The swimming pattern of each mouse was 
monitored and recorded for 60 sec using the SMART-LD program. Consolidated 
spatial memory was estimated by the time spent in the target quadrant area. 
 
5.2.3.2 The passive avoidance test 
The passive avoidance test was performed 48 hours after the probe test. The passive 
avoidance response was determined using a “step-through” apparatus (Med 
Associates Inc., Vermont, USA) that is divided into an illuminated compartment and a 
dark compartment (each 20.3 × 15.9 × 21.3 cm) adjoining each other through a small 
gate with a grid floor, 3.175-mm stainless steel rods set 8 mm apart. On the first day 
(i.e. Day 7), the mice were placed in the illuminated compartment facing away from 
the dark compartment for the learning trial. When the mice moved completely into 
the dark compartment, it received an electric shock (0.45 mA, 3 s duration). Twenty-
four hours after learning trial (i.e. Day 8), each mouse was placed in the illuminated 
compartment and the latency period until the animal entered the dark compartment 
was determined and defined as the step-through latency (i.e. Testing trial). The cut-
off time for the examination was 180 seconds. 
 
5.2.4 Tissue extraction from Tg2576 mouse 
The hippocampus was dissected from parasagittal brain slices; nucleus accumbens 
(NAc) and striatum were dissected from coronal brain slices; the ventral tegmental 
area (VTA) was dissected from horizontal brain slices. Tissues were homogenized in 
RIPA buffer (containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM MgCl2, 1 mM 
EDTA, 1% Triton X-100, 0.25% sodium deoxycholate, 0.1% SDS, 1 mM sodium 
orthovanadate, 5 mM β-glycerophosphate, 5 mM NaF and protease inhibitor cocktail), 
sonicated and incubated on ice for 30 min. The samples were then centrifuged at 
14,000g for 20 min and protein concentrations of the supernatant were determined 
by the Bradford method. 
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5.2.5 Proteasome activity assay 
5.2.5.1 Using the purified human 20S proteasome 
Purified 20S human proteasomes (from Boston Biochem) were used to assess the in 
vitro activity of proteasome inhibitors. In 96-well format, 20S proteasomes (0.5 
μg/mL) were mixed with proteasome inhibitors in assay buffer (20 mM Tris-HCl, 0.5 
mM EDTA, 0.035% SDS) at room temperature for 30 min, prior to the addition of 
fluorogenic substrates to a final assay volume of 100 μL. Fluorogenic substrates used 
in this study are: Suc-LLVY-AMC (CT-L activity, 100 μM), Ac-PAL-AMC (LMP2, 100 
μM), Ac-WLA-AMC (β5, 20 µM), Ac-nLPnLD-AMC (β1,100 µM), and Ac-ANW-AMC (β5i, 
100 µM). The fluorescence of liberated AMC was measured over a period of 90 min at 
360 and 460 nm on a SpectraMax M5 fluorescence plate reader (Molecular Devices). 
 
5.2.5.1 Using the isolated mouse tissue samples  
To measure proteasome activity in brain tissues isolated from Tg2576 mice, tissues 
were homogenized in RIPA buffer (50 mM Tris Cl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 
1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 1% aprotinin, 50 mM NaF) and 
sonicated. Samples were then centrifuged for 20 min at 14,000g (4 °C). After the 
Bradford protein assay of the supernatant, samples were loaded onto a 96-well plate 
prior to the addition of the substrate (Ac-PAL-AMC) at 37 °C. Fluorescence was 
recorded for 90 min using a Synergy-HT (Bio Tek) plate reader. To exclude non-
proteasomal substrate degradation, control samples were incubated with YU102 (1 
μM) for 60 min at 37 °C before loading on the plate and values were subtracted from 
lysates incubated with DMSO control. 
 
5.2.6 Immunoblotting analysis 
Total cell lysates containing equivalent protein content were separated by 12% SDS-
PAGE and transferred to polyvinylidene difluoride membranes (Millipore) via a semi-
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dry transfer. Membranes were then blocked in 5% non-fat dry milk (Bio-Rad) in Tris-
buffered saline with 0.05% Tween-20 (TBST) for 1 h at room temperature. After 5 
times wash with PBS, membranes were probed with primary antibodies (anti-LMP2, 
anti-LMP7, and anti- β-actin, Abcam) in 3% BSA followed by a rabbit horseradish 
peroxidase-conjugated secondary antibody (GE Healthcare). β-actin was used as a gel 
loading control. SuperSignal West Femto Chemiluminescent Substrate (Thermo 
Scientific) and X-ray film (Thermo Scientific) were used for visualization. 
 
5.2.7 Measurement of Aβ 
Hippocampal Aβ1-42 levels were determined using an ELISA Kit (Cusabio Biotech Co., 
Ltd., Wilmington, DE, USA). Experiments were performed according to the 
manufacturer’s instructions. In brief, samples and standards were added into the pre-
coated plate and incubated for 2 hours at 37℃. Biotinylated antibodies (1x) were 
added to each well and incubated 1 hour at 37℃. After washing, HRP-avidin (1x) was 
added and incubated for 30 minutes at 37℃. After washing, TMB substrate was added 
to each well. After the addition of stop solution, the absorbance was measured at 450 
nm using a microplate reader (Sunrise™, TECAN, Switzerland). 
 
5.2.8 Thioflavin T staining 
Frozen hippocampal tissues were cut into 30 μm sections by using cryostat 
microtome (Leica CM1850; Leica Microsystems). The pieces of tissues were 
thoroughly washed with distilled water for 5 min, and then transferred to gelatin 
coated slides and placed in 1% Thioflavine T for 5 min, followed by dehydration using 
ascending grades of ethanol (50%, 70%, 90%, and 100%) for 2 min in each grade. The 
dehydrated samples were then mounted with mounting medium (FluoromountTM, 
Sigma). Thioflavin T staining was examined by using a fluorescence microscope. 
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5.2.9 Cresyl violet staining  
Frozen hippocampal tissues were cut into 30 μm sections by using cryostat 
microtome (Leica CM1850; Leica Microsystems, Korea). The pieces of tissues were 
thoroughly washed with PBS to remove excess fixative agent, and then transferred to 
gelatin coated slices and stained with 0.1% Cresyl violet (2-5 minutes) to identify 
cortical layers and cytoarchitectural features of isocortical region. Next, the resulting 
sections were washed with distill water and dehydrated by using ascending grades of 
ethanol (50%, 70%, 90%, and 100%) for 2 min in each grade followed by a 1-min 
immersion in a 1:1 mixture of absolute alcohol and xylene. The sections were then 
rinsed with xylene for 5-10 min and mounted with mounting medium (CYTOSEALTM 
XYL; Thermo Scientific, USA). The same areas of tissues were photographed (100x). 
 
5.2.10 Tau aggregation assay 
For microscopic image analysis, cells were plated in a black transparent 96-well plate. 
The next day, tau-BiFC cells were treated with the okadaic acid or forskolin at various 
concentrations. After, 2, 9, 19, and 24 hr of incubation, the entire 96-well plate was 
automatically imaged under same exposure by using Operetta® High Contents 
Screening System (equipped with a 10x and 20X dry lenses). The cellular intensities 
of tau-BiFC fluorescence were analyzed using Harmony 3.1 software. Error bars 
indicate s.d. from two independent experiments. Each experiment was performed as 
triplicate. 
 
5.2.11 Immunohistochemical staining 
Frozen hippocampal tissues were cut into 30 μm thick sections and stored free 
floating in cryoprotectant solution (30% ethylene glycol, 20% glycerol, 50 mM 
sodium phosphate buffer, pH 7.4) at 4 °C until further use. For immunohistochemical 
staining, sections were rinsed in 1× PBS, incubated in blocking buffer (1× PBS 
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containing 0.3% Triton X-100 and 10% normal goat serum) for 1 hr at room 
temperature and further incubated overnight with primary antibodies for GFAP 
(1:1000; Abcam) or Iba-1 (1:500; Abcam) diluted in 1× PBS/ 0.3% triton X-100/ 5% 
normal goat serum at 4 °C. Sections were washed with 1× PBS to remove excessive 
primary antibodies, incubated with species specific peroxidase-coupled secondary 
antibodies (goat anti-mouse or goat anti-rabbit (1:300, Abcam)) diluted in 1× PBS/ 
0.3% Triton X-100/ 5% normal goat serum. The resulting sections were incubated 
for 1 h on a shaker at RT and developed with liquid diaminobezadine (DAB) (Dako, 
K3647). Sections were then counterstained with matured hematoxylin, followed by 
dehydration in an ascending alcohol series before covering using Roti®-Histokitt II 
mounting medium. For Congo red staining, free-floating cerebral sections were 
mounted on glass slides and incubated in stock solution I (0.5 M NaCl in 80% ethanol, 
1% NaOH) for 20 min and subsequently stock solution II (8.6 mM Congo red in stock 
solution I, 1% NaOH) for 45 min. After rinsing twice in absolute ethanol, sections were 
counterstained with mature hematoxylin and dehydrated in ascending alcohol series 
before rinsing twice in 98% xylene for 1 min, and finally mounted with Roti®-
Histokitt II mounting medium. Stereological analysis was performed using a Stereo 
Investigator system (MicroBrightField) and DV-47d camera (MicroBrightField) 
mounted on an Olympus BX53 microscope (Olympus, Germany). Fluorescence 
imaging was performed using an Olympus XM10 monochrome fluorescence CCD 
camera (Olympus, Germany). 
 
5.2.12 Membrane-based cytokine array 
A cytokine antibody array assay was performed with a mouse cytokine array kit (R&D 
Systems) according to the manufacturer’s protocol. Briefly, BV-2 cells, seeded in a 12-
well plate at 2 x 105 cells per well, were incubated with 1 µg/mL of E. coli 055:B5 
lipopolysaccharide (Thermo Scientific) and  3 µM of YU102 or ONX 0914 for 24 hr. 
The supernatants from BV-2 cells were collected and centrifuged to remove cell 
debris. The resulting supernatants were then incubated with assay membranes 
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precoated with capture antibodies overnight at 4°C. After rinsing the membranes 
with wash buffer, a detection antibody was added using streptavidin–horseradish 
peroxidase (HRP) and Chemi Reagent Mix. The immunoblot images were visualized 
using SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific) and 
X-ray film (Thermo Scientific or GeneMate). 
 
5.2.13  Enzyme-linked immunosorbent assay (ELISA) 
BV-2 microglial cells (2.5 × 105 cells/well) were seeded in 12-well culture plates. After 
overnight incubation, cells were simultaneously treated with 1 µg/mL of E. coli LPS 
and various concentrations of YU102, YU102 epimer, or ONX 0914 for 24 h. 
Supernatants were analyzed for the quantification of released pro-inflammatory 
cytokines, using Mouse IL-1α, IL-6, or CCL12/MCP-5 uncoated sandwich ELISA Kit 
(Thermo Scientific) on high-binding ELISA plates according to the manufacturer’s 
protocol. Briefly, standards and samples were incubated on capture antibody coated 
plate for 2 h at room temperature, followed by incubation with detection antibody for 
1 h and then Avidin-HRP for 30 minutes. For visualization, substrate solution was 
added to each well, and then the reaction was stopped by the addition of stop solution 
(2N H2SO4). Absorbance was measured by ELISA microplate reader at 450 nm 
wavelength. 
 
5.2.14 RPE flat mounts 
Retinal pigment epithelium (RPE) of Tg2576 was isolated and incubated with β-
catenin (1:100 diluted) overnight at 4°C. After incubation with primary antibody, the 
RPE tissues were further incubated with Alexa 555-conjugated secondary antibody 
(Invitrogen; A21422; 1:1000 diluted) at room temperature for 2 hours. Sample was 
observed by using a confocal microscope (Carl Zeiss, LSM 800) 
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5.2.15 Cell-based RPE degeneration assay 
ARPE-19 cells were seeded at 80,000 cells/well in 24-well plate with auto-coverglass. 
Cells were treated with 50 ng/mL of TNF-α and incubated for additional 24 hr before 
treatment with vehicle, 1 μM of YU102 or YU102 epi. After incubation, cells were fixed 
with 4% paraformaldehyde for 1 h at room temperature. Cells were then blocked with 
3% BSA for 1 h after permeabilized with 0.2% Triton X-100 for 15 min. Cells were 
incubated overnight at 4°C with the primary antibodies (1:100; E-cadherin; Abcam; 
ab1416, 1:100; Vimentin; Abcam; ab92547) and treated with the fluorescence-
conjugated secondary antibodies (1:1000; Alexa Fluor 488 and 555) for 2 h at room 
temperature in the dark. The cells were washed 3 times with PBS for 10 min each 
after every step, and the nuclei were stained with DAPI (1:1000; Invitrogen, D1306). 
Cells were mounted on the coverslip with ProLong Gold antifade reagent (Invitrogen 
Life Technologies, P36934) and observed with a confocal microscope (Carl Zeiss, 
LSM800).       
  
5.2.16 Cell viability assay 
BV-2, EOC-20, and WI-38 cells were seeded at 5,000 cells/well and RPMI 8226 cells 
were seeded at 10,000 cells/well in 96-well plates. Following overnight incubation, 
cells were treated with carfilzomib, ONX0914 or YU102 at indicated concentrations 
for 72 h. Cell viability was determined by CellTiter 96 AQueous One Solution Cell 
Proliferation assay (Promega) following manufacturer’s protocol. Absorbance at 490 
nm was measured using a SpectraMax M5 microplate reader (Molecular Devices). 
 
5.2.17 Statistics 
Results are expressed as means  ±  S.D. Statistical significance of the observed group 
differences was determined using Student’s t-test or two-way ANOVA followed by 
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Dunnette’s post hoc test. Significance was set at p < 0.05 for all tests. All statistical 
analyses were carried out using GraphPad Prism 8.0.1 (GraphPad Software).  
 
5.3 Results 
5.3.1 YU102 improves cognitive function in an LPS-induced mouse model of 
neuroinflammation 
Since previous data suggested an increase in iP gene expression during aging 
and in plaque-associated glia cells in APP/PS1 mice we examined the impacts of 
proteasome inhibition on cognitive impairments using several subunit-selective 
proteasome inhibitors [240] (Figure 5.1A). We first ensured that cP or iP selective 
inhibitors displayed the expected inhibitory profile by conducting proteasome 
activity assays with subunit-selective fluorogenic substrates in purified human 20S 
constitutive and immunoproteasomes (Figure 5.1B). We set out to examine whether 
inhibition of IP activity might reduce or eliminate cognitive impairments caused by 
AD. For an initial assessment, we chose to use a lipopolysaccharide (LPS)-induced 
inflammation mouse model, known to display AD-like cognitive impairment [297, 
298]. Specifically, 8-week old ICR mice were treated with daily injections of LPS for 5 
days (250 µg/day), followed by i.p. delivery of iP-selective YU102 (10 mg/kg), PR-
924 (10 mg/kg), CP-selective PR-825 (2 mg/kg) or conventional PIs (carfilzomib 
5mg/kg, bortezomib 1 mg/kg) twice a week for 3 weeks. At the end of treatment 
period, the Morris water maze test was performed to evaluate cognitive functioning 
in mice. All mice were trained three times on the same day prior to daily 
measurements of escape latency and distance traveled over 5 consecutive days. Of 
note, none of the tested mice displayed any irregularity in their motility. 
Unfortunately, almost all the mice treated with general PIs (carfilzomib, bortezomib; 
inhibit both CP and IP) did not survive to complete the test. In contrast, the mice 
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treated with YU102 displayed no signs of overt toxicity and exhibited improved 
distance and escape latency compared to mice treated with LPS alone. Mice treated 
with PR-825 (X-selective) or PR-924 (LMP7-selective) displayed only mild 
improvement in performance relative to LPS-treated control mice (Figure 5.2 A&B). 
Next, we conducted probe trials to measure the ability of memory. As shown in Figure 
5.2C, YU102-treated group displayed the better performance, spending longer time 
in the target quadrant compared to the control groups. One day after the probe tests, 
we performed the passive avoidance assay by measuring an average step-through 
latency of YU102-treated group or control groups (vehicle only or LPS treated group) 
(Figure 5.3). Consistent with previous the Morris water maze assay data, YU102 
treated group showed the improved performance compared to LPS-treated group. 
This result was intriguing in that LMP2 inhibition through pharmacological inhibition 
or genetic knockout of LMP2 previously showed no effect on proinflammatory 
cytokine release from LPS-stimulated human PBMCs or mouse peritoneal 
macrophages [56, 294]. Taken together, we suggested that IP inhibition, especially 
LMP2 inhibition could improve cognitive impairment caused by a LPS-induced 
neuroinflammation. 
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Figure 5.1 Structures and Proteasome inhibitory activity of PIs 
A. structures of immunoproteasome inhibitors (YU102, PR-924), YU102 epimer (an 
inactive stereoisomer of YU102), and constitutive proteasome inhibitor (PR-825) are 
shown. B. Proteasome inhibitory activity profiles of YU102, YU102 epimer, PR-924, 
and PR-825 in human purified 20S proteasome are shown. Data is shown as mean ± 
SD derived from a non-linear regression based on n=3 replicates per compound per 
concentration. aIC50 values were determined from competition assays in Raji cell 
lysates [84]. bIC50 values were approximated from ProCISE assay using A20 murine 
lymphoma cells [52]. cIC50 values were from ProCISE ELISA using MOLT-4 human 
leukemia cells [332].   
A 
B 
115 
 
 
 
Figure 5.2 The Morris water maze tests in LPS-induced mouse model 
YU102 (10mg/Kg), PR-924 (10mg/kg), PR-825 (2mg/kg), carfilzomib (5mg/kg) and 
bortezomib (1mg/kg) were treated in LPS-induced mouse model. Mice treated 
carfilzomib or bortezomib could not survive. Escape latency time in the target 
quadrant (A) and escape distance (B) of the mice were shown. Statistical analysis was 
performed via two-way ANOVA. *Differences in escape latency on days 4-6 and 
distance on day 6 between LPS-treated and YU102 treated were statistically 
significant (p-value < 0.05, n=5). C. Tg2576 mice were evaluated in the probe trial. 
(This experiment was performed by In Jun Yeo from Dr. Jin Tae Hong’s group in the 
college of Pharmacy, Chungbuk National University, Korea) 
A 
C
 
B 
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Figure 5.3 The passive avoidance test in LPS-induced mouse model 
One day after the probe trials, LPS-induced mice were evaluated in passive avoidance 
test among vehicle only, LPS-injected (250 µg/day, for 5days), or LPS injected and 
then YU102-treated group (10mg/kg, twice a week for 3 weeks). (This experiment 
was performed by In Jun Yeo from Dr. Jin Tae Hong’s group in the college of Pharmacy, 
Chungbuk National University, Korea) 
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5.3.2 YU102 ameliorates AD-related cognitive impairment in the Tg2576 mouse 
model 
Encouraged by our initial assessment showing the promising activity of YU102 
in a mouse model of LPS-induced inflammation (Figures 5.2 and 5.3), we wanted to 
further verify its efficacy using a more relevant animal model of AD. To this end, we 
chose the APP transgenic mouse model (also known as Tg2576), which exhibit age-
associated deficits in learning and memory with Aβ deposits as a result of expression 
of KM670/671NL mutant human APP. To demonstrate target engagement and 
specificity of YU102, an inactive stereoisomer of YU102 (YU102 epi, a negative 
control) were also included. First, 10-month old APPsw mice (Tg2576 mice) were 
treated with YU102 via the intraperitoneal (i.p.) twice a week for 3 weeks and then 
the Morris water maze test was performed, followed by a single probe trial 24 hours 
later o and passive avoidance test to investigate the impacts of YU102 treatment on 
spatial learning and memory in a Tg2576 mouse model. Specifically, all mice were 
trained for three times for 5 days before behavior investigation. Initially, escape 
latency and distance traveled were measured on a daily-basis over a 5-day period. 
Remarkably, as shown in Figure 5.4, consistent with the results obtained from the 
LPS-induced inflammation model, mice treated with YU-102 exhibited significantly 
shorter distance and escape latency than those treated with inactive YU102 epi or 
vehicle (Figure 5.4 A & B). This strongly supports that the efficacy of YU102 is 
mediated through LMP2 inhibition. One day after the Morris water maze test, we next 
measured the ability of mouse to maintain memory on probe trials. In line with the 
results from the water maze tests, YU102-treated mice performed significantly better 
than control groups: the percentage of time spent in the target quadrant was 21.25 ± 
2.71% for YU102-treated group and ~10-14.50 ± 1.03% for control groups (Figure 
5.4C). Sequentially, a step-through latency test was performed a day after the probe 
trial. While Tg2565-vehicle treated group showed an average step-through latency of 
~44 sec, YU102-treated group had ~128 sec, displaying considerably improved fear-
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associated short-term memory, suggesting LMP2 activity improves cognitive function 
in Tg2576 mice (Figure 5.5).  
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Figure 5.4 The Morris water maze tests in Tg2565 mice 
YU102 ameliorates cognitive deficits in Tg2576 mice. Escape latency time in the 
target quadrant (A) and escape distance (B) were shown. Statistical analysis was 
performed via two-way ANOVA. *Difference in escape latency on days 4-5 or distance 
on days 3-5 between control and YU102-treated mice was statistically significant (p-
value < 0.05, n=8). C. Upon the completion of the Morris water maze test, Tg2576 mice 
were evaluated in the probe trial. Statistical analysis for probe trial was performed 
via Student-t test. Differences in time spent in target quadrant between control and 
YU102-treated mice were statistically significant (p-value < 0.05, n=8) (This 
experiment was performed by In Jun Yeo from Dr. Jin Tae Hong’s group in the college 
of Pharmacy, Chungbuk National University, Korea) 
A 
C
 
B 
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Figure 5.5 The passive avoidance test in Tg2576 mice 
One day after the probe trials, Tg2565 mice were evaluated in passive avoidance test 
between vehicle only and YU102-treated group (10mg/kg, twice a week for 3 weeks). 
Statistical analysis for passive avoidance was performed via Student-t test. Difference 
in step through latency between control and YU102-treated mice were statistically 
significant (p-value < 0.05, n=8) (This experiment was performed by In Jun Yeo from 
Dr. Jin Tae Hong’s group in the college of Pharmacy, Chungbuk National University, 
Korea) 
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5.3.3 YU102 selectively inhibits LMP2 activity in the Tg2576 mouse model 
After behavioral testing, mice were sacrificed and proteasome activities in 
different organ tissues were measured to examine target engagement and specificity 
of YU102 by measuring the remaining LMP2 activity in mice. As shown in Figure 5.6, 
YU102 inhibited LMP2 but not Y or LMP7/X-associated proteasome activity 
(measured as the CT-L activity). This target engagement investigation was possible 
due to the irreversible covalent binding of YU102 to LMP2. It should be also noted 
that the family of peptide α,β-epoxyketones such as YU102 have been shown to be 
highly selective for the proteasome with no significant off-targets reported so far 44-
48. As such, we expect that YU102 will likely have no major off-target interactions. 
The relatively modest LMP2 inhibition observed in monitored tissues is likely due to 
the synthesis of new proteasome catalytic subunits during the gap between the final 
YU102 treatment and sacrifice. Taken together, the results support that selective 
inhibition of LMP2 activity improves cognitive function in the APP transgenic mouse 
model of AD. 
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Figure 5.6 The proteasome activities in organ tissues collected from Tg2565 
mice 
Upon the completion of the behavior test, proteasome activities in heart and lung 
collected from Tg2576 mice treated with vehicle, YU102 (10 mg/kg), or YU102 
epimer (10 mg/kg) were measured using fluorogenic substrates. Error bars are 
standard deviation derived from three technical replicates. *Differences in LMP2 
inhibitory activity in spleen, liver, heart, and lung tissues between YU102-treated and 
YU102 epi-treated group were statistically significant (p-value < 0.05, n=3). 
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5.3.4 YU102 exerts its efficacy independently of Aβ deposition  
Given the data showing improved learning and memory of LMP2 inhibitor-
treated mouse models of AD, we initially suspected that YU102 exert their activity by 
promoting Aβ clearance in the brain of Tg2576 mice via an undefined mechanism. To 
examine such a possibility, we measured the levels of soluble Aβ in hippocampal 
tissues isolated from the brain of Tg2576 mice using an enzyme-linked 
immunosorbent assay (ELISA) and levels of amyloid fibrils were measured via the 
fluorescent dye Thioflavin T. Interestingly, we observed no difference in Aβ 
deposition between the mice treated with YU102 and vehicle-treated mice (Figure 
5.7 A & B). The results can be cautiously interpreted that YU102 may exert its anti-
AD efficacy in the Tg2576 model independently of Aβ deposition or clearance. This 
result is highly intriguing considering that several drugs with proven Aβ-clearing 
ability have failed to demonstrate clinically meaningful efficacy in recent high-profile 
phase 3 clinical trials [171]. 
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Figure 5.7 Efficacy of YU102 in Tg2576 mice on Aβ deposition 
A. ELISA-based quantification of Aβ1-42 in hippocampal tissues isolated from Tg2576 
mice. The difference in the levels of Aβ1-42 between vehicle control and YU102-treated 
mice was not statistically significant (p-value > 0.1, n=3). Statistical analysis of ELISA 
results was performed via Student t-test. B. Thioflavin T staining of Aβ fibrils in 
hippocampal tissue sections from Tg2576 mice.  (This experiment was performed by 
In Jun Yeo from Dr. Jin Tae Hong’s group in the college of Pharmacy, Chungbuk 
National University, Korea)  
A 
B 
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5.3.5 Efficacy of YU102 is unrelated to tau or neuroprotection 
5.3.5.1 Effect of YU102 on Tau aggregation 
 
Tau polymerization has been considered as one of main culprits behind AD 
etiology and a potential target for therapeutic intervention [299]. In Tg2576 mice, 
hyperphosphorylated tau oligomerizes in an age-dependent manner that coincides 
with the appearance of Aβ oligomers and declining cognitive function [300-304]. 
Given this, we wondered whether YU102 exerts its anti-AD efficacy by inhibiting the 
oligomerization of hyperphosphorylated tau. To quickly test this possibility, we used 
HEK293-tau-BiFC (bimolecular fluorescence complementation) cell-based assay, in 
which tau oligomerization and aggregation induced by an activator of protein kinase 
A (PKA) such as forskolin or thapsigargin can be detected via the reconstitution of the 
fluorescent protein Venus.  As shown in Figure 5.8, YU102 did not inhibit thapsigargin 
or forskolin-induced tau aggregation. Low tau-BiFC intensity observed at high 
concentration of LMP2 inhibitors (30-100µM) were due to cell death. Taken together, 
these results demonstrate that the YU102-induced improvement in cognitive 
behavior in Tg2576 mice is independent of Aβ deposition and tau aggregation. 
 
5.3.5.2 Effect of YU102 on neuroprotection 
Since accumulation of misfolded proteins such as Aβ in cells induces immune 
response and cell death, we next tested whether YU102 has neuroprotective effects 
in Tg2576 mice. To examine this, we performed Cresyl violet staining experiments on 
neuronal tissues isolated from the brains of Tg2576 mice. We found no noticeable 
difference in the total number of neurons between mouse groups treated with YU102, 
YU102 epi, or vehicle (Figure 5.9). Although we found no evidence that YU102 affects 
neuron survival, these results could also be affected by the relatively short drug 
treatment period (~3 weeks). 
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Figure 5.8 Efficacy of YU102 in Tg2576 mice on tau aggregation 
YU102 has no effect on tau aggregation. Thapsigargin (1µM) or forskolin (1µM) 
induces tau aggregation in tau-BiFC cells, activating a tau BiFC fluorescence signal 
that can be detected. (This experiment was performed by Hyun Jung Jeong from Dr. 
Yun Kyung Kim at KIST, Korea.) 
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Figure 5.9 Efficacy of YU102 in Tg2576 mice on neuroprotection 
YU102 displays no neuroprotective effects during the experimental period. 
Hippocampal tissues isolated from the brains of Tg2576 mice were stained with 
Cresyl violet, a marker for Nissl substance in neurons. (This experiment was 
performed by In Jun Yeo from Dr. Jin Tae Hong’s group in the college of Pharmacy, 
Chungbuk National University, Korea.)  
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5.3.6 YU102 reduces the number of reactive astrocytes and microglia in Tg2576 mice 
Neuroinflammation is reported to be closely linked to the development and 
progression of AD and inflammation in the brain is characterized by the activation of 
neuroglia cells (microglia and astrocytes), which was considered as a major culprit 
behind AD pathology and a key drug target in neurodegenerative diseases [249, 305-
307]. Also, Aβ and LPS have been shown to distinctly alter cytokine production 
profiles and induce innate immune signaling and microglial activation [308-311]. 
Therefore, we set out to investigate whether YU102 blocks the activation of glial cells 
in brain tissues of Tg2576 mice. When immunostaining for GFAP and Iba1, known 
markers of reactive astrocytes and microglia, respectively, was performed, we 
observed that the numbers of positively stained cells in hippocampal tissues were 
significantly fewer in mice treated with YU102 than in the control group (Figure 
5.10A). COX-2 also known as a proinflammatory enzyme is overexpressed in human 
AD and mouse AD models [312-314]. As shown in Figure 5.10B, expression of COX-2 
was also significantly lower in hippocampal tissues of mice treated with YU102 
compared to control mice. Taken together, these data suggest that LMP2 is involved 
in the activation of glia cells and that LMP2 inhibition suppresses activation of 
astrocytes and microglia and thus suppresses neuroinflammation. 
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Figure 5.10 YU102 reduces the numbers of activated astrocytes and microglia 
A. Reactive astrocytes (left) and microglial cells (right) were visualized using 
respective markers (GFAP and Iba1) in hippocampal tissues from Tg2576 mice. B. 
Expression levels of COX-2 in hippocampal tissues in Tg2576 mice treated with 
YU102 are lower than in the control Tg2576 mice. (This experiment was performed 
by In Jun Yeo from Dr. Jin Tae Hong’s group in the college of Pharmacy, Chungbuk 
National University, Korea)  
A 
B 
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5.3.7 LMP2 inhibition attenuates pro-inflammatory cytokine production in microglial 
cells 
5.3.7.1 Membrane-based cytokine array 
 
It is well-documented that activated microglia synthesize and release pro-
inflammatory cytokines and play an important role in AD progression. Furthermore, 
secretion of pro-inflammatory cytokines by microglia and associated changes in 
phagocytic and neuroprotective properties are a major contributing factor to the 
recently recognized “cellular” phase of Alzheimer’s disease [315, 316]. Since YU102 
reduced the number of activated microglia cells in Tg2576 mice, we suspected that it 
could exert their anti-AD efficacy by suppressing pro-inflammatory cytokine 
production. Therefore, we examined whether YU102 can suppress the production of 
pro-inflammatory cytokines in microglial cells. To do this, we used an immortalized 
murine microglial cell line BV-2, commonly used as a substitute for primary microglia 
in many experimental settings [317]. BV-2 cells were pre-incubated with YU102 for 
2 hr before LPS treatment to upregulate cytokines. After additional 24 hr incubation, 
cell supernatants were collected and analyzed for the levels of 40 cytokines and 
chemokines using a membrane-based mouse cytokine antibody array (Figure 5.11A). 
BV-2 cells treated with LPS only exhibited elevated levels of multiple pro-
inflammatory cytokines and chemokines compared to unstimulated cells (Figure 5.11 
B & C). As previously reported, ONX 0914, a selective inhibitor of immuno-subunit 
LMP7, suppressed LPS-induced production of pro-inflammatory cytokines, such as 
IL-1β, CCL12/MCP-5, IL-6 and CCL5/RANTES [52]. Similarly, YU102 also significantly 
attenuates production of IL-1α, CCL12/MCP-5, and to a lesser degree, IL-6 which were 
induced by LPS. The result that YU102, a LMP2 inhibitor, strongly suppressed the 
production of several proinflammatory cytokines was highly intriguing. Previously, 
inhibitors of LMP2, such as KZR-504, displayed little to no suppression of cytokine 
production (e.g. IL-1β, IL-6, IL-8, TNF-α) in human peripheral blood mononuclear 
cells (PBMCs) [56]. We suspect these contradictory results are due to cell type 
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(organ)-specific role of LMP2, indicating a distinct role of LMP2 in microglia 
inflammatory response. Altogether, these findings demonstrate that inhibition of 
LMP2 ameliorates disease in mouse models of AD and may offer a promising strategy 
for AD treatment. 
 
5.3.7.2 Enzyme-linked immunosorbent assay (ELISA) 
Since we observed the effect of YU102 on the production of pro-inflammatory 
cytokines and chemokines in LPS-stimulated BV-2 microglial cells using a mouse 
cytokine membrane array, we further verified the effect of YU102 on microglia 
cytokine release in vitro by measuring the levels of individual cytokines in LPS-
stimulated BV-2 cells treated with vehicle or YU102 via enzyme-linked 
immunosorbent assay (ELISA). Consistent with membrane-based cytokine array, as 
shown in Figure 5.12, LPS-activated BV-2 cells secreted significantly increased 
amounts of pro-inflammatory cytokines IL-α and IL-6 and mildly upregulated the 
level of pro-inflammatory chemokine CCL12. Most notably, inhibition of LMP2 by 
YU102 substantially attenuated the levels of IL-α, IL-6, and CCL12 production. Taken 
together, our results suggest a specific role for LMP2 in modulating the glial response 
during LPS-induced neuroinflammation. 
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Figure 5.11 Mouse cytokine array in microglial BV-2 cells  
A 
B 
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Figure 5.11 Mouse cytokine array in microglial BV-2 cells (continued)  
Suppression of cytokine production by YU102 in LPS-stimulated BV-2 cells. A. 
Cytokine and chemokine protein array blots of BV-2 cells treated with vehicle, LPS 
(1µg/mL) alone, and YU102 (3µM) or ONX0914 (3µM) with LPS (1µg/mL). B. The 
amount of each cytokine or chemokine was relative to the mean of the intensity of 
corresponding spots from vehicle control sample. Each cytokine or chemokine has 
duplicate detection spots. Graph depicts the fold change of each cytokine or 
chemokine (mean). Arrow labels indicate cytokines that are most significantly 
impacted by YU102. C. Full suppression profile of cytokine production by YU102 in 
LPS-stimulated BV-2 cells using a mouse cytokine array kit (R&D Systems). The 
amount of each cytokine or chemokine was relative to the mean of the intensity of 
corresponding spots from vehicle control sample. Each cytokine or chemokine has 
duplicate detection spots. The graph depicts the mean spot pixel density from the 
arrays using Quantity One software (Bio-rad) analysis. 
 
  
C
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Figure 5.12 Enzyme-linked immunosorbent assay (ELISA) in BV-2 cells  
Cytokine production in LPS-stimulated BV-2 cells with and without YU102 was 
determined by ELISA. Effect of YU102 on the release of cytokines in LPS-stimulated 
BV-2 cells. BV-2 cells were incubated with LPS (1µg/mL) and YU102 or YU102 epimer 
for 24 h. All values are expressed as mean ± SEM from three independent experiments. 
*Differences in suppression of IL-1α and IL-6 levels between YU102-treated and 
YU102 epi-treated group were statistically significant (p-value < 0.05, n=3).   
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5.3.8 YU102 selectively inhibits LMP2 subunit in microglial cells 
In line with selectivity data of YU102 in different organ tissues isolated from 
Tg2576 mice after behavior test, we confirmed selective LMP2 inhibition by YU102 
using microglial cell line model BV-2 cells. First, we conducted proteasome activity 
assay with subunit-selective fluorogenic substrates in BV-2 cells. YU102 significantly 
inhibits LMP2 subunit at low concentrations (0.1 and 0.3µM), while ONX0914, a 
LMP7-selective inhibitor, achieved > 50% inhibition of both LMP2 and LMP7 activity 
at 0.3µM concentration in BV-2 cells (Figure 5.13A). We next assessed the specificity 
of YU102 toward the LMP2 subunit by mobility shift assays with western blot to 
visualize the YU102-LMP2 covalent adduct (Figure 5.13B). For mobility shift assay, 
where indicated, BV-2 cells were treated with DMSO, 0.1-3µM YU102 or YU102 
epimer for 4 h. For competition assay, BV-2 cells were pre-treated with 1µM YU102 
for 1 h, prior to the addition of the addition of 0.1-3µM YU102 epimer. The covalent 
binding of YU102 to LMP2 is shown by a complete upward shift of the LMP2 band in 
BV-2 cells upon treatment with YU102 compared to YU102 epimer. Conversely, 
covalent modification of proteasome catalytic subunits LMP7 and X by YU102 was not 
observed (data now shown). These results clearly showed that YU102 covalently 
binds LMP2, but not the other catalytic subunits of proteasomes in BV-2 cells, 
indicating its high specificity toward the LMP2 subunit.  
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Figure 5.13 Selectivity of YU102 in BV-2 cells  
A. Remaining catalytic activities of individual subunits in LPS-stimulated BV-2 cells 4 
h after treatment with YU102 (top) or ONX0914 (bottom) at various concentrations. 
Data are presented as mean ± SEM from three independent experiments. B. 
Visualization of target engagement via immublotting YU102: LMP2 covalent adduct 
on the SDS-PAGE. BV-2 cells were treated with YU102 for 1 h at 0.3, 1, or 3µM 
concentrations.   
A 
B 
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5.3.9 Broad impacts of YU102 on neuroinflammatory disorders in Tg2576 mice 
Several recent studies demonstrated that Aβ deposits are consistently found 
in the retina from patients with age-related macular degeneration (AMD) and can be 
positively correlated with the disease progress [318]. In addition, it has been 
reported that inflammation triggered by Aβ is a major contributor to RPE (retinal 
pigment epithelium) abnormalities in APP transgenic animal models including 
Tg2576 [319-321]. Given this, we investigated the effects of YU102 on RPE 
degeneration in Tg2576 mice, a characteristic of age-related macular degeneration 
(AMD) [318]. RPE samples were collected from Tg2576 mice treated with vehicle, 
YU102, or YU102 epi and subjected to immunohistochemical staining with an anti-β-
catenin primary antibody followed by Alexa 555-conjugated secondary antibody. As 
shown in top, Figure 5.14, the orderly mosaic structure of RPE typically observed in 
non-transgenic mice was severely damaged in Tg2576 mice treated with vehicle only, 
as previously reported [322]. However, YU102 provided Tg2576 mice with almost 
complete protection from RPE damage, showing the typical mosaic structure of RPE 
(middle, Figure 5.14). In contrast, YU102 epi (an inactive stereoisomer of YU102) 
provided no protection from RPE mosaic disruption (bottom, Figure 5.14), indicating 
that YU102 protected the structure integrity of retina from degeneration through 
LMP2 inhibition. 
 
 
5.3.10 The effect of YU102 on human RPE cells degeneration 
In order to further verify in vivo observation in Figure 5.13, we conducted in 
vitro studies using the human RPE cell line ARPE-19, known to form a mosaic-like 
monolayer. Inflammatory stimuli, such as TNF-α, induce epithelial-to-mesenchymal 
transition (EMT) with concomitant morphological and molecular changes in ARPE-
19. Normal ARPE-19 cells maintain the epithelial morphology and show high 
expression of E-cadherin in cell-cell junction with little expression of Vimentin in the 
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cytoplasm [323]. However, in response to TNF-α, ARPE-19 cells underwent EMT and 
exhibited downregulation of E-cadherin and overexpression of Vimentin in the 
cytoplasm. Notable, when the RPE cells were treated with LMP2 inhibitor, YU102, 
TNA-α-induced EMT was significantly suppressed through the maintenance of E-
cadherin expression and inhibition of Vimentin expression (Figure 5.15). These 
results suggest suppression of TNF-α-induced inflammatory response. These findings 
are in line with a previous report that in response to TNF-α, RPE cells isolated from 
LMP2 knockout mice exhibit diminished NF-κB activation [324]. In summary, the 
result supports that LMP2 inhibition may control inflammatory response of RPE cells 
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Figure 5.14 Effect of YU102 on in vivo RPE degeneration  
YU102 inhibits in vivo RPE (retinal pigment epithelium) degeneration. RPE from eyes 
of Tg2576 mice treated with vehicle, YU102 or YU102 epi were isolated and 
immunostained to establish boundaries of RPE monolayers. (This experiment was 
performed by Areun Baek from Dr. Dong Eun Kim’s group in the department of 
Bioscience and Biotechnology, Konkuk University, Korea)   
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Figure 5.15 Effect of YU102 on in vitro RPE degeneration 
YU102 inhibits in vitro RPE degeneration. EMT in the human RPE cell line ARPE-19 
was induced by TNF-α. TNFα-induced EMT in ARPE-19 cells was attenuated by 
YU102 but not YU102 epimer. EMT is detected by upregulation of vimentin and 
downregulation of E-cadherin. (This experiment was performed by Areun Baek from 
Dr. Dong Eun Kim’s group in the department of Bioscience and Biotechnology, 
Konkuk University, Korea)   
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5.3.11 YU102 has no cytotoxic effect 
It is critical that LMP2 inhibition leads no major adverse effects in the body for 
the use of chronic AD therapy. Throughout our in vivo efficacy studies of YU102, we 
observed no signs of overt toxicities in mice treated with YU102. To further verify the 
non-toxicity of YU102 in cell culture, we incubated a panel of cell lines (WI-38, a 
human lung fibroblast cell line; RPMI 8266, a human myeloma cell line; BV-2 and EOC-
20, two murine microglial cell lines) with YU102, ONX 0914 (an LMP7 inhibitor), or 
carfilzomib (an FDA-approved inhibitor targeting multiple proteasome subunits 
including β5 and β5i, a positive control known to induce cell death) for 2-3 days. We 
then performed cell viability assays using CellTiter 96 AQueous One Solution. YU102 
showed no negative impact on the viability of all four cell lines at relevant 
concentrations (Table 5.1 and Figure 5.16). In comparison, ONX 0914 was much more 
toxic to these cell lines than YU102 and has a low therapeutic margin. Intriguingly, 
activation via LPS pretreatment further sensitized the two microglial cell lines (BV-2, 
and EOC-20 cell lines) to ONX0914, not to YU102, which is in line with previous 
reports demonstrating near complete cell death in a primary neuron model with 48 
hours of 500 nM ONX0914 (Figure 5.16) [325]. Taken together, these results 
potentially indicate that LMP2 inhibition may offer a safer therapeutic strategy for 
neurodegenerative diseases than LMP7 inhibition. 
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Table 5.1 Cytotoxicity of proteasome inhibitors in BV-2, EOC20, RPMI 8226, 
and WI-38 cells 
 
Inhibitor 
Cell viability (IC50, nM) 
BV-2 EOC-20 RPMI8226 WI-38 
Carfilzomib 1576.2 ± 300.8 
781.1 
± 154.7 
8.7 
± 3.1 
17.9 
± 5.9 
ONX 0914 1,327 ± 374.8 
1030 
± 552.3 
154.1 
± 23.4 
682.7 
± 66.4 
YU102 ˃10,000 ˃10,000 ˃10,000 ˃10,000 
 
Data is shown as mean ± SD derived from a non-linear regression based on n=3 
replicates per compound per concentration 
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Figure 5.16 Cell viability graphs for YU102, and ONX0914 in various cell lines 
EOC-20 and WI-38 cells were seeded at 5,000 cells/well and RPMI 8226 cells were 
seeded at 10,000 cells/well in 96-well plates. Following overnight incubation, cells 
were treated with YU102 or ONX0914 at indicated concentrations for 48 h (EOC-20 
with or without 24h 1µg/mL LPS pretreatment) or 72 h (RPMI 8266 and WI-38). Cell 
viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation 
assay (Promega) following manufacturer’s protocol. Absorbance at 490 nm was 
measured using a SpectraMax M5 microplate reader (Molecular Devices). 
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5.4 Discussion 
Alzheimer’s disease is increasing rapidly in frequency as the world’s population 
ages and more people enter the major risk period for this age-related disorder. 
Current drug treatment for AD patients, essentially symptomatic, is based on three 
cholinesterase inhibitors (rivastigmine, donepezil and galantamine) and memantine, 
affecting the glutamatergic system. These drugs do not represent a cure, as they do 
not arrest the progression of dementia, but rather, they lead to a temporary 
slowdown in the loss of cognitive. In recent years, several drug candidates (either 
monoclonal antibodies or small molecules) have been pursued based on the amyloid 
hypothesis. However, none of these drugs displayed meaningful cognitive 
improvement in phase III clinical trials, threatening the validity of the amyloid 
hypothesis. Therefore, new therapies are urgently needed to treat affected patients 
and to prevent, or improve the symptoms of AD. 
In the current study, we report that YU102, inhibiting LMP2 subunit selectively 
in brain, ameliorates memory dysfunction in Tg2576 independent of Aβ deposition 
and tau aggregation. In addition, we demonstrated that YU102 blocks activation of 
astrocytes and microglia in Tg2576 mice and inhibits LMP2 subunit selectively in BV-
2 microglia cells with high specificity. We also utilized a mouse cytokine array kit and 
ELISA assays, measuring the levels of pro-inflammatory cytokines and chemokines 
response following LPS-induced microglial activation in cells. Our data showed that 
YU102 suppresses the production of IL-1α, IL-1β, IL-6, and CCL12 in microglial cells, 
which are important factors involved in the progression of neuroinflammatory 
disease, indicating LMP2 inhibition can exhibit anti-neuroinflammatory activity in 
vitro by attenuating the production of pro-inflammatory cytokines and chemokines. 
This result was particularly surprising given previous reports demonstrating that 
LMP2-selective inhibitors have no effect on pro-inflammatory cytokine production 
25 or NF-kB activation in human PBMCs or cancers [56, 295]. In microglial BV-2 cells, 
the potent LMP7-selective inhibitor ONX 0914 appears to be nearly as effective in 
suppressing pro-inflammatory cytokine production as YU102. At the same time, ONX 
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0914 was much more cytotoxic than YU102 in all tested cell lines. Overall, it seems 
that LMP2 may offer a better therapeutic target than LMP7 for the development of 
drugs to treat neurodegenerative diseases. 
Several studies have shown that Aβ deposition was detected in the retinas, 
which might be responsible for the pathogenesis of AMD by causing RPE 
degeneration from different AD transgenic mouse models, resulting in both functional 
and structural retinal abnormalities [319, 326-330]. In this study, we also observed 
RPE damage in eyes isolated from Tg2576 mice and found YU102 protected from 
blocking RPE degeneration. This was further verified by the effect of YU102 on RPE 
degeneration in human ARPE-19 cells. We found YU102 suppressed TNF-α-induced 
EMT induction, suggesting YU102 may alter signaling pathways which mediate TNF-
α-induced EMT such as TGF-β signaling pathway [331]. 
In summary, we showed that YU102, a LMP2-selective inhibitor, improves 
cognitive dysfunctions in AD mouse models without affecting Aβ deposition and tau 
polymerization. In addition, we found that YU102 suppresses production of pro-
inflammatory cytokines in microglial cells, revealing a previously unrecognized role 
of LMP2 in microglia-mediated innate immune responses. Finally, the present study 
demonstrated that inhibition of LMP2 possesses anti-neuroinflammatory properties 
that suppress microglial activation and represents a potential therapeutic target for 
neuroinflammatory diseases such as AD and AMD.  
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CHAPTER 6. SUMMARY  
Therapeutic agents targeting specific molecular lesions in cancer cells have 
substantially improved the survival of cancer patients. But, the inevitable emergence 
of drug-resistance presents a formidable challenge for clinicians. Currently, there are 
no available strategies in the clinic to combat PI-resistance due to a lack of knowledge 
regarding the PI response mechanisms. In order to address this problem, extensive 
effort has been put forth over the last decade toward improving our understanding of 
the mechanisms responsible for PI resistance. Although several mechanisms of PI 
resistance have been proposed previously, these mechanisms have not been 
validated clinically and cannot explain all PI resistance observed. Recently, several 
studies have shown that UPS-targeting inhibitors including PIs other than Btz retain 
anticancer activity in Btz-resistant MM cells, indicating that the UPS remains essential 
in these cells and alternative PIs can overcome Btz resistance. However, mechanistic 
understanding of intrinsic Cfz resistance is limited due to a lack of suitable cell-based 
models.  
To elucidate intrinsic Cfz resistance in cancer cells, we identified that H727 
human bronchial carcinoid cells are inherently resistant to Cfz and utilized this cell 
line to test our hypothesis. We found that proteasome function remained vital to the 
survival of Cfz-resistant cancer cells, and that targeting the proteasome using 
alternative PIs is a good strategy to overcome Cfz resistance. Additionally, results 
obtained from alterations in the composition of proteasome catalytic subunits in the 
cell line model showed a potential link may exist between the composition of 
proteasome catalytic subunits and the cellular response to Cfz. These findings 
support that proteasome catalytic subunit composition may play a major role in 
differential responses to PIs among MM patients. Thus, it is crucial to determine 
composition of proteasome subunits in cancer cells with intrinsic/acquired PI 
resistance to design a new effective treatment for MM patients who do not respond 
or have developed resistance to PIs. In addition, this study demonstrates that 
proteasome inhibition by alternative PIs may still be a valid therapeutic strategy for 
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patients with relapsed MM after having received treatment with Cfz. Although we 
believe that cell line model studies provide solid proof of concept evidence for the use 
of PIs in Cfz-resistant cells, it will be important to validate these findings using clinical 
samples.  
Our studies may provide important insights into the design and further 
optimization of PIs with improved potency in Cfz-resistant cells. With this in mind, 
we designed and synthesized novel epoxyketone-based PIs by structural 
modifications at the P1′ site. We observed that a Cfz analog, harboring a hydroxyl 
substituent at its P1′ position, was highly cytotoxic against de novo or acquired Cfz 
resistant cell lines. These findings support that peptide epoxyketones incorporating 
P1′-targeting moieties may have the potential to bypass resistance mechanisms 
associated with Cfz and to provide additional clinical options for patients resistant to 
Cfz. Moving forward, further studies regarding the efficacy of peptide epoxyketones 
incorporating P1′-targeting moieties should be investigated in animal models and 
ultimately in clinically-relevant primary cells derived from patient who do not 
respond to PI therapies. 
 
Despite extensive efforts to develop therapies for neurodegenerative diseases such 
as AD and AMD, effective treatments are not yet available. As such, there is an urgent 
need to reshape the drug target landscape and develop therapies against these 
diseases. In recent years, dysregulated immune response in the CNS has garnered 
increased attention as a target of neurodegenerative diseases. The IP, understood to 
contribute to and regulate immune response, has only recently become targetable by 
selective inhibitors. While inhibitors targeting the IP catalytic subunit LMP7 are 
currently being investigated in preclinical and clinical models of multiple 
inflammatory diseases, their efficacy in neurodegenerative diseases has never been 
evaluated. Although the IP found to be highly expressed in microglial cells from AD 
patients and mouse models, the exact role of IP in AD pathology remains poorly 
understood to date.  
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To address the role of IP in AD, we investigated the impact of IP inhibition on 
cognitive function in AD mouse models and observed that YU102, a selective inhibitor 
of IP catalytic subunit LMP2, is highly effective in improving cognitive behavior of AD 
mice without affecting Aβ deposits or tau polymerization, strongly warranting further 
investigation of LMP2 inhibition in clinical settings as a new strategy for AD therapy.    
Considering the success of YU102 in improving the treatment of AD, we believe that 
any effort to identify AD drug candidates will extend from the exciting preliminary 
results obtained using YU102 to clinical trials. Thus, further medicinal chemistry 
efforts by our group have been yielding a library of structurally unique and diversified 
compounds. Our current compound, YU102, is quite promising in terms of the 
potency in inhibiting LMP2 and acceptable target selectivity. Thus, our optimization 
effort will focus on improving not just the potency and specificity, but also 
pharmaceutical properties. We now aim to develop most promising YU102 analogs 
(acyclic and macrocyclic) based on the potency, target selectivity and chemical 
stability. In addition, further optimization of YU102 will be necessary to BBB 
permeability. As well, in vivo efficacy and PK properties will move into the next 
phases of AD drug development.   
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